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ABSTRACT
Despite a strong clinical demand for tissue replacement therapies, few tissueengineered constructs (TECs) have attained FDA approval. Fewer still demonstrate long
term viability of implanted cells, with root causes of failure of these devices identified as
poor cell retention, poor vascularization, and inflammation following implantation.
Focusing on the first two of these issues, we attempt to create a rapidly vascularizable
TEC by optimizing a novel vascular implant model developed in our laboratory: the
scaffold-free, prevascular endothelial-fibroblast construct (SPEC). The optimization
process calls on a hybrid in vivo, in vitro, and in silico approach.
We first developed an in vivo temporal model of TEC vascularization by
comparing endothelial invasion, cord development, anastomosis, and vessel maturation
dynamics of SPECs to avascular grafts such as fibroblast-only spheroids and silicone
implants. While the existing microvessel architecture of the SPECs confers an
advantage in anastomosis and endothelial infiltration of an implant in the first 12 hours
post-implantation, poor lumen patency limits the rate of vessel development in the TECs.
Perfusion is apparent at later time points (24-72 h) in both SPECs and fibroblast-only
spheroids. Analysis of in vivo vascularization dynamics is augmented by a control flow
simulation model which reveals that delayed vascular development coincides with poor
accumulation of pro-angiogenic factors such as VEGF.
Our in vivo observations drove corrections of our SPEC model, with efforts
undertaken to improve lumen formation during the in vitro development period. These
approaches include pre-dosing implants with pro-angiogenic factors such as VEGF,
inducing endothelial cell realignments in a perfusion chamber, and incorporation of
perivascular cells to improve patency of forming tubes. Recombinant human VEGF165
(rhVEGF165) dosing was most consistently associated with increased formation of
ii

endothelial-lined lumens, with a dose (ranging from 0-50 ng/mL) and time dependent
increase in diameters of these lumens during SPEC formation.
Finally, we generated computational models of SPEC formation in a rhVEGF165
field in order to combine our observations of endothelial clustering behavior, SPEC
reorganization, and dose/time dependent cord hollowing behavior observed in vitro with
existing stochastic models of tissue assembly and cell-cell interface optimization.
Through careful control of model parameters, we generated a list of in silico simulations
to enable optimization of vascularization response, ultimately resulting in a list of
candidate treatments built on the backbone of VEGF pre-dosing. This candidate list can
serve as a starting point for future experiments, with a goal of rapid and stable lumen
formation and blood perfusion.

iii

ACKNOWLEDGMENTS
Dr. Michael J. Yost was instrumental in my development as a researcher, encouraging a
systems biology approach to vascular tissue engineering while ensuring experiments
were conducted a careful attention to statistical design and practical utility. Heather
Bainbridge provided the bulk of my training in biological science. She has been a terrific
source of both intellectual and emotional support. Sarah Grace Dennis has walked much
of the path towards our doctorates with me and has been a great source of support as a
fellow researcher and as a friend.
My friends throughout the PhD experience, Nate Jensen, Brandon Young, and
Danh Tran, share a great deal of credit for my continued sanity. My sister, Sweta
Pattanaik, has been an early supporter of my work, providing external validation of my
work when I sorely needed it. Finally, and most importantly by far, I acknowledge the
support of my parents, Sumanta Pattanaik and Laxmi Mohanty. They have indulged and
encouraged my academic fancies without even a moment’s hesitation. They have
listened to a thousand rants, innumerous half-baked theories, and an unconscionable
amount of posturing on my end, grounding me when necessary and letting me loose
when it truly helped.

iv

TABLE OF CONTENTS

Page

TITLE PAGE................................................................................................................. i

ABSTRACT .............................................................................................................. ii-iii

ACKNOWLEDGEMENTS ............................................................................................iv

LIST OF TABLES ...................................................................................................... viii

LIST OF FIGURES .................................................................................................. ix-xi

CHAPTER

I.

POTENTIAL AND LIMITATION OF TISSUE ENGINEERING................ 1-11

1.1 Tissue Engineering Market ............................................................. 1
1.2 Root Cause Analysis of Failure of Autologous TECs ................... 2-5
1.3 Rationale for Scaffold-Free Tissue Engineering ........................... 5-9
1.4 The Vascularization Challenge .................................................. 9-11
1.5 Scope of Research in Thesis ........................................................ 11

II.

A TEMPORAL MODEL OF TISSUE VASCULARIZATION .................. 12-52

2.1 In Vivo TEC Vascularization Dynamics .................................... 12-33
2.2 Computational Control Flow Model of TEC Vascularization ..... 33-48
2.3 Chapter Specific Methods........................................................ 48-52
v

III.

STRATEGIES TO IMPROVE SPEC VASCULARIZATION ................. 53-69

3.1 Dosing SPECs with Vascular Endothelial Growth Factor ........ 53-59
3.2 Growth of SPECs in Perfusion Chambers ............................... 59-62
3.3 Incorporation of Pericytes into SPECs ..................................... 62-69
3.4 Chapter Specific Methods............................................................. 69

IV.

MODELING VEGF-INDUCED LUMEN FORMATION IN SPECS ...... 70-102

4.1 Endothelial Condensation and Clustering with VEGF .............. 70-75
4.2 Role of Fibroblast Behavior in VEGF-treated Implants ............. 75-76
4.3 Mechanism of Lumen Formation and Role of VEGF ................ 76-78
4.4 Phenotype Changes After VEGF-Treatment of SPECs ........... 78-80
4.5 Cell Death in Treated SPECs .................................................. 80-85
4.6 Cellular Potts Modeling Framework ......................................... 85-90
4.7 VEGF-Activation of Endothelial Cells ....................................... 90-92
4.8 Polarization Model and Anoikis Model of Lumen Formation... 93-102
V.

FUTURE DIRECTIONS................................................................... 103-109

5.1 SPEC Simulation Results .................................................... 103-104
5.2 Re-Scaling SPECs .............................................................. 104-106
5.3 Role of Inflammation and Immunity in TEC Vascularization . 106-111
5.1 Conclusion.................................................................................. 111

VI.

GENERAL METHODS .................................................................... 112-128

6.1 Primary Human Cell Culture ................................................ 112-113
6.2 Rodent Cell Extraction and Culture ...................................... 114-116
6.3 Immunohistochemistry and Immunofluorescence ................ 116-118
vi

LIST OF TABLES
Table

Page

1.1

FDA Premarket Approved Cell-based Tissue Engineered Products .......... 3

2.1

Parameters Used in Simulink® Simulation. ............................................... 36

4.1

Potential Candidate Treatments. ......................................................... 97-99

vii

LIST OF FIGURES

Figure

Page

1.1

Root Cause Analysis of TEC Failures ........................................................ 4

2.1

A Temporal Model of Vascularization in TECs ......................................... 14

2.2

Western Blots of Vascularization Markers ................................................ 18

2.3

Whole-mount Immunofluorescence Imaging of SPECs ............................ 19

2.4

Time-lapse Images of GFP-Tagged HAMECs in SPECs .......................... 20

2.5

Time-series of SPEC and FOS Microvessel Invasion and Formation ....... 23

2.6

Host versus Implant-derived Microvessels ............................................... 24

2.7

Mural Cell Involvement in Vessel Formation ............................................. 25

2.8

TUNEL Staining of Implants ..................................................................... 26

2.9

Dye Perfusion of Implants ........................................................................ 27

2.10

Graphs of Microvessel Density and Capsule Penetration .................... 31-32

2.11

Diagram of SPEC Vascularization ............................................................ 35

2.12

VEGF Diffusion Simulation Block ............................................................. 39

viii

2.13

Endothelial Cell Infiltration Block .............................................................. 42

2.14

Oxygenation Simulation Block .................................................................. 44

2.15

Combined Simulink® Block Diagram of TEC Vascularization .................... 45

2.16

Simulink® Results .................................................................................... 56

3.1

VEGF Dose-Dependent Changes in SPEC Formation ............................. 56

3.2

Graph of Average Lumen Diameter in SPECs .......................................... 57

3.3

Effect of Time of Treatment on SPEC Formation...................................... 58

3.4

F-actin Reorganization in Day 3 VEGF-treated SPECs ............................ 59

3.5

SPEC Growth in Perfusion Chamber........................................................ 61

3.6

CellTracker and CD31 Stains of Pericyte-SPECs ..................................... 66

3.7

Smooth Muscle Actin Expression in Pericyte-SPECs ............................... 67

3.8

SPECs with Invading Pericytes ................................................................ 68

4.1

SPECs and Endothelial Spheroids Condensing with VEGF Treatment .... 71

4.2

Mitotracker DeepRed Labeled Cocultures ................................................ 72

4.3

pStat3 ELISA ........................................................................................... 74

ix

4.4

VEGF-Treated Fibroblasts ....................................................................... 75

4.5

Western Blots of VEGF-Treated SPECs .................................................. 79

4.6

TUNEL Staining of Untreated SPECs....................................................... 80

4.7

TUNEL Staining of VEGF ......................................................................... 81

4.8

2,4 Dinitrophenol Treated SPECs ............................................................ 82

4.9

Trypan Blue Dye Uptake of Adherent and Non-adherent Cocultures ........ 84

4.10

Stochastic Modeling Framework .............................................................. 85

4.11

Lattice Representation of SPEC in VEGF Field ........................................ 86

4.12

Cellular Potts Model Equations ................................................................ 88

4.13

Metropolis Algorithm ................................................................................ 89

4.14

Dose/Response Curve for rhVEGH-165 ................................................... 91

4.15

Hidden Markov Chain For VEGF/VEGFR2 Binding .................................. 92

4.16

Polarization Model.................................................................................... 93

4.17

Anoikis Model ........................................................................................... 94

4.18

Simulation of VEGF Dose-Dependent Lumen Formation ......................... 95

x

4.19

Optimization Experiments and Regression Coefficients ......................... 101

5.1

Deposition of Complement on SPECs .................................................... 107

5.2

Recruitment of Myeloperoxidase-positive Cells to SPECs ...................... 108

xi

1 POTENTIAL AND LIMITATION OF TISSUE
ENGINEERING
1.1 Tissue Engineering Market
Tissue engineered constructs (TECs), cell- or biomaterial-based devices
designed to restore the function of damaged or dysfunctional tissue, have expanded the
world of therapeutic possibilities for clinician scientists. Tissue engineering evokes an
image of customizable “bedside to bench to bedside” research, in which researchers
rapidly develop patient-specific solutions to organ deficits discovered in the hospital
setting [1]. These innovations have the potential to positively impact millions of patients
with a variety of pathologies, in some of the largest markets in healthcare. The reported
potential market value for skin repair products alone, for instance, is $5.945 billion, with
devices such as acellular IntegraTM artificial skin products and living keratinocytefibroblast engineered skin (ApligrafTM) receiving premarket approval from the Food and
Drug Administration (FDA) in the ‘90s to address this demand [2]. Recognizing the lifesaving potential of regenerative medicine therapies, the United States congress
approved, as of December 2016, a regenerative medicine advanced therapy designation
to permit expedited development and review of tissue engineering advances that
address a serious unmet need or treat a life-threatening condition [3].As of 2018, 21
companies are commercially developing TECs, with an estimated $9 billion in sales.[4]
Despite this promising outlook, clinical applications of a subset of TECs,
exogenously constructed cellular implants, have been surprisingly limited. A few of the
barriers to implementation are posed by ethical considerations and the regulatory burden
faced by cell-based technologies. The FDA, which regulates all surgically implantable
devices, included cellular implants under a category for human cell, tissue, and cellular
1

and tissue-based products (HCT/P) [1, 5]. Biologics, including HCT/Ps, can be subject to
dozens of years of clinical testing and have developmental costs averaging $802 million
to $2.6 billion per product [6]. The difficulties encountered in attaining approval for cellbased products may be pushing investigators toward the development of acellular
biologic products.

1.2 Root Cause Analysis of Failure of Autologous Cell-derived TECs
Aside from regulatory hurdles for cellular products, researchers face more
fundamental and scientific concerns: How does one guarantee that implanted cells,
autologous or otherwise, survive to engraft and function appropriately in the host? Table
1.1 describes a list of cell-based tissue engineered products that have received FDA
premarket approval for clinical therapies. Basic science literature used to justify medical
device approval does not adequately quantify the degree of cell survival. Many device
descriptions treat cell survival as relatively insignificant to the overall effectiveness of the
product. There is a troubling dearth of literature addressing and quantifying early cell
survival within living tissue engineered constructs. Instead, investigators report
outcomes indirectly associated with cell viability such as the presence of immune
infiltrate, evidence of ischemia, or indications of poor cell retention.

2

Table 1.1: FDA Premarket Approved Cell-based Tissue Engineered Products
Product Name
Cell Type, Approved Use Cell Survival Information
Carticel[7] (now
Autologous Chondrocytes
Demonstrate persistence of
MACI)
autologous chondrocytes 14
Use: Repair of
weeks post-injection in goat
symptomatic articular
model; lack quantitative analysis
cartilage defects of the
and note leakage of cells out of
femoral condyle
site of defect [6, 8]
laViv[7]
Autologous Fibroblasts
Demonstrated survival of human
dermal fibroblasts injected into
Use: Improve appearance hypodermis for 8 weeks. No
of moderate to severe
quantitative data [6, 9]
nasolabial fold wrinkles
[10]
Celution
Autologous AdiposeReports improved graft survival
Derived Regenerative
(quantified as fat volume
Cells (ADRCs)
percentage) with addition of
ADRCs [11].
Use: Improve hand
function in Scleroderma,
Peltoniemi et al argue inclusion of
Improve function and
ADRCs does not augment fat
symptoms in osteoarthritis, graft survival [6, 12]
Treatment of Thermal
Burn Injuries
Epicel[13]
Dressing comprised of
No quantitative data for
sheets of autologous
proportion of implanted cells
keratinocytes (Cultured
remaining after graft placement.
Epidermal Autograft)
Similar graft take rates to splitthickness skin grafts [14]
Use: Patients with deep
dermal or full thickness
burns comprising a total
body surface area ≥ 30%
Apligraf/GINTUIT[7]
2-layer dressing
Cells do not survive in vivo
comprised of living
application (termed a “temporal
allogeneic keratinocytes
dressing”) [15]
and fibroblasts derived
from neonatal foreskins.

Dermagraft[16]

Use: For full-thickness
neuropathic diabetic foot
ulcers of greater than 3
weeks duration, nonresponsive to conventional
therapy
Dressing composed of
fibroblasts derived from
neonatal fibroblasts [17]
Use: For full-thickness
diabetic foot ulcers of
3

Persistence of some dermagraft
cells by PCR at 6-months postimplantation. No quantitative
data analysis.[16]

greater than 6 weeks
duration in patients with
adequate blood supply

In lieu of TEC cell viability information, we conducted a root-cause analysis of causes of
graft failure in autologous tissue transplantation experiment conducted by our laboratory
and collaborators, as well as other researchers (Figure 1.1), to develop hypotheses
concerning potential causes for poor cell viability in tissue engineered constructs.
Our laboratory has focused on ventral hernia repair, a valuable target for skeletal muscle

Root Cause Analysis:
Cell Displacement
Cells disperse after
scaffold degradation

Inflammation
Capsule formation
Immune Cell infiltration

↓ Cell retention

↑ Pro-inflammatory molecules

Poor Cell
Viability in
TECs

↓ Oxygen tension
↓ Blood Perfusion
↓ Proangiogenic factors
Ischemia

FIGURE 1.1: A root-cause-analysis (RCA) was conducted on skeletal muscle grafts,
including autologous flaps, collagen tubes, and bioengineered skeletal muscle. The various
findings clustered around three major causes of graft failure: inflammation (either due to
surgical insult or foreign body response); ischemia (low tissue oxygenation or blood
perfusion); poor cell localization and/or cell displacement from original construct
(degradation of scaffolding material such as collagen tubes, poor retention of cell solutions
at sites of injection).

and skin replacement. Fann et al. compared outcomes associated with autologous
muscle flap and collagen-tube-associated repair, following the processes of tissue
cellularization, vascularization, and, ultimately muscle repair.[18] Tissue fibrosis, noted by
formation of a collagen-rich, dense capsule around implanted tissue, was occasionally
noted within a few weeks of implantation, a characteristic of a foreign body response.
4

Ischemic insults were suspected due to ubiquity of low oxygen tension in all implants
within the first 8-hours following implantation, and a lack of a nearby mature vasculature,
represented by a lack of red blood cell-perfused capillaries[19, 20]. Follow up protein
expression assays showed a delayed expression of vascular endothelial growth factor
and an early elevation of pro-inflammatory molecules associated with a sterile
inflammatory response, such as Interleukin-1β.[19] Localization of cells associated with
collagen-tubes became progressively harder following degradation of the biomaterial
components.
Clustered together in a fishbone-diagram (Figure 1.1), we identify 3 root causes
of implant failure: Cell displacement following implantation; ischemic insult; inflammatory
insult. Within this dissertation, we limit our scope to evaluating strategies to contend with
the first two of these issues. These broad foci form the basis of our attempt at creating a
scaffold-free, rapidly vascularizable tissue engineered construct.

1.3 Rationale for Scaffold-Free Tissue Engineering
Scaffold-free tissue engineering is our main approach to improving cell retention
following implantation of TECs. This method of tissue engineering is a direct response to
the limitations of cell suspension-based replacement therapies as well as scaffold-based
tissue engineering. Traditionally, tissue engineering approaches have either involved
direct injection of high-density cell suspensions to a site of injury or implanting scaffolds
seeded with the cellular payload. The simplest design for a cellular product would be
direct delivery of cell suspensions. In the context of muscle repair, for instance, this
might involve replenishing skeletal myocytes. However, direct implantation of cell
suspensions into injured tissue has not been highly successful, both in the context of
muscle regeneration and in other organs. Allotransplantation of myoblasts into patients
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with Duchenne’s muscular dystrophy, a condition characterized by muscle degeneration,
showed promising results, with 3.5-26% of muscle fibers in the host expressing donor
dystrophin.[21] However, in a similar study, only 30% of labeled injected myoblasts were
found in dystrophic host mice, and only 1% remained after 4 days [3]. Myocardial
restoration with cell therapy shows similar issues. Only 0.44% of injected mesenchymal
stem cells into the left-ventricle of mice survived after 4 days.[22] Intracoronary injections
of autologous bone marrow cells near a site of infarction resulted in a retention of 1.32.6% of cells in the infarcted zone [23] within 75 minutes of injection. Direct
intramyocardial injection of cells such as peripheral blood mononuclear cells, showed an
improvement to 11% cell retention within an hour of delivery [24]. However, of the
remaining cells, more than 50% die within 24 hrs., likely due to a combination of
ischemic and inflammatory pressures.[23, 25]
Poor cell retention in direct cellular transplantation necessitates other
approaches to ensuring stable delivery of cells. This involves creation of a tissue
engineered construct (TEC), where cells and supportive biomaterials are combined to
create tissue in vitro. Scaffold-based tissue engineering techniques presuppose a
desired tissue architecture and attempt to forcibly confine cells to this framework. Cell
orientation in scaffolds is defined by mechanical stimuli and, in more advanced cases,
embedded growth hormones and adhesion molecules. Following degradation of the
implanted scaffold, which is necessary to ensure TEC biocompatibility, these physical
guidance cues are lost. This often results in poor retention of cells in the initial implant
locus. Cells seeded in tissue engineered vascular grafts, for instance, do not remain in
the devices following implantation.[6] The inventors contend that cell retention was not
necessary for functional incorporation of the graft as the host inflammatory response to
implanted cells improved recruitment of host vascular cells; however, inflammatory
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angiogenesis is typically transient. Additionally, if engrafted cells will not maintain the
structure and form provided by scaffolding, organ recapitulation can become difficult,
especially when contending with patients truly deficient in certain cell populations (e.g.
type 1 diabetics lacking islet cells).[26]
Scaffold-free tissue engineering, on the other hand, does not relay on transient
physical cues. It involves self-assembly or self-organization of cells without requiring
cells to adhere to an exogenously derived three-dimensional structure[27, 28]. Scaffoldfree TEC technology gained traction in cartilage engineering in the early 2000s through
efforts to induce chondrogenesis in vitro in scaffold-free bioreactors to facilitate cartilage
repair.[29, 30] The technology was employed to avoid biocompatibility issues associated
with various scaffolding biomaterials[29] and to allow recapitulation of stromal tissue, such
as cartilage, without the addition of structural components.
The terms self-assembly and self-organization denote distinct subsets of
scaffold-free tissue engineering. Self-assembly refers to the process of spontaneous cell
reorganization without an external force in a closed system, while self-organization
involves an external signal or force, as seen in rotational cultures or bioreactors[28] Thus
far, we have focused on the self-assembly subset of scaffold-free tissue engineering.
The advantage of self-assembly is that cells, having adopted an energetically favorable
architecture in vitro of their own volition, should not readily disassemble following
implantation into a host. The process takes on an additional level of complexity when
two or more cell types are intermixed at ratios to approximate the heterogeneity of
complex native tissue. The differential adhesion hypothesis (DAH), which relates the
organization of tissues composed of different cell types to the behavior of immiscible
liquids, has often been used to model the behavior of cells with differing adhesive, or
cell-cell binding capacities. When considering liquids, molecules spontaneously orient
themselves to maximize adhesive bonding or, in other words, minimize the “adhesive”
7

free energy of a system [31]. Qualitatively speaking, this would involve merging identical
liquids to reduce interfacial tension, rounding-up of irregular structures[31], and
envelopment of liquid phases with higher surface tensions by those with lower surface
tension [32]. Foty and Steinberg theorized that this could be translated to modeling
cellular behavior, noting that clonal populations derived from a single population of
nonadhesive L929 cells could be transfected with different levels of N, P, and Ecadherins to model different cell-cell binding behaviors [33]. Increased cadherin
expression resulted in increased cadherin-cadherin cross bridging between cells,
measurable as an increased aggregate surface tension. Low cadherin-expressing cells
enveloped high-cadherin expressing cell populations in mixtures, appearing to
recapitulate the behavior of immiscible liquids of different relative surface tensions

[33]

.

The simplicity of DAH and its potential to guide tissue engineering is very
alluring. Individual spheroids, cultured in a non-adherent hanging drop were shown to
merge into a single spheroid in order to minimize interfacial tension[32], supporting the
plausibility of a modular design for tissue engineered constructs, one of the long term
goals of H+ lab. In fact, within this dissertation, we explore a potential role of DAH
theory in modeling vascular implant assembly (Chapter 4). However, the lab has noted
several inconsistencies with this approach to modeling cell behavior in tissue engineered
constructs. Czajka et al demonstrated that this cell sorting behavior between individual
spheroids was reliant on a 360° range of movement. When spheroids were confined to
linear molds to enable tissue formation, the resulting constructs deformed upon release
from the molds.[34] Once formed, individual spheroids generated a tissue cortical
cytoskeleton and extracellular matrix that further complicated the make-up of the initial
cell-suspension. The spheroid fusion process would necessitate reorganization of the
cytoskeleton, and spatial constraints imposed on cell movement within the mold results
in an imbalance of cytoskeletal tensions among the spheroid modules within the
8

tissue.[34] While these findings may merely pose a possible cytoskeletal rate limitation to
modelling of spheroid fusion behavior, a more direct challenge to the DAH has been
suggested by the Yost lab when exposing spheroids to 2,4 dinitrophenol, a drug that
inhibits energy production within mitochondria of cells without inducing cell death. The
spheroid fusion process was abrogated with drug dosing and rescued with recovery of
ATP generation in cells. This suggests that differential cell-cell binding behavior and a
drive to minimize adhesion free-energy alone could not account cell reorganization. DAH
might allow a simplified model of the behavior of nonadherent cells in embryological
conditions or in a hanging drop culture, but formation of mature tissues is clearly a more
complicated process, requiring a more thorough understanding of cellular energetics in
tissue engineering before a modular approach can be considered.

1.4 The Vascularization Challenge
While cell retention and cellular product design are important pre-implantation
considerations, the true test of a products viability begins a few hours after implantation.
The implant must be incorporated into the host, and to do so it must anastomose to the
host vasculature. The notion that vascularization is crucial to the long-term survival of
implanted tissue is not controversial. In the absence of oxygen, nutrient, and waste
exchange, no population of cells can survive. However, the speed at which
vascularization poses a challenge to implantable tissue grafts lacking a vascular pedicle
is daunting. In the context of muscle repair, even autologous free muscle transfer to a
site of injury results in severe hypoxia of the implanted tissue within 8hrs of implantation.
[35]

Hypoxia prevents constitutive degradation of hypoxia-inducible factor HIF-1α, whose

targets, normally, include genes upregulating angiogenesis (e.g. VEGF-A expression),
hematopoiesis, vasodilation, and anaerobic glycolysis in order to address the low
oxygen tension. [36] However, most of this pro-cell survival effect is contingent on an
9

existing vasculature and some residual low levels of environmental oxygen. In the
absence of either, severe hypoxia appears to lead to a mixture of apoptosis and
necrosis. Shimizu et al, observed, for example, that overexpression of anti-apoptotic
factors such as Bcl-2 or Bcl-XL reduces hypoxia-induced cell death. [37] Necrosis, on the
other hand, appears to involve elevation of cytosolic Ca2+ concentration concurrent with
decrease of ATP, which leads to activation of calcium-dependent proteases.[37]]
To mitigate the destructive potential of hypoxia or anoxia on cellular implants, rapid
anastomosis of a construct to the host vasculature is desired. Unfortunately, we cannot
rely on purely host-driven angiogenic pathways to vascular implants. Utzinger et al
tracked migration and growth of neovessel fragments in collagen in vitro, and noted
approximately 5 um/hr rate of microvessel formation. [38] Host vessel growth into a 200
um to 400 um diameter rod of engineered tissue, with dimensions exceeding those
needed to permit diffusion mediated exchange of oxygen, nutrients, and waste[39], could
require one to two days at this rate. This issue is compounded when considering to the
scaffold-free design. High density cell aggregation comes at the cost of permeability to
oxygen and nutrients from the host vasculature [40] coupled by an increased cellular
metabolic demand compared to hydrogel scaffolding. An internal network of vessels
must form and form rapidly to enable construction of scaffold-free TECS with a thickness
exceeding 500 um. [40] In such cases, a part scaffold-based design might even be
preferable to scaffold-free designs, to permit greater nutrient and oxygen exchange while
lowering the overall metabolic demand of the implant.

1.5 Scope of Dissertation
In this dissertation, the scope of the research is confined to scaffold-free TEC
vascularization. Notably, we exclude cell-based immunotherapies and cancer therapies

10

from our focus on tissue engineered products and viability as it extends beyond wellestablished definitions of tissue engineering as a means of restoring or improving tissue
functions.[4] Our focus is primarily on tissue grafts that would aid in the repair of dermal
or musculoskeletal injuries.
Among the list of principal “causes” from our root-cause-analysis of failure of tissue
grafts (Figure 1.1), we focus primarily on the need for rapid vascularization and
structural integrity of TECs. However, we acknowledge that immune response or
rejection of TEC components is at least as important a factor in TEC viability. Current
and future research aims will address experiments needed to address innate and
adaptive immunity in the context of graft survival.

11

2 A TEMPORAL MODEL OF TISSUE VASCULARIZATION
*original work introduced in this chapter was published in part in Bioresearch Open
Access[41]

2.1 In Vivo TEC Vascularization Dynamics
2.1.1 Rational for Developing a Temporal Model of TEC Vascularization
While tissue engineering literature often lacks consistent documentation of cell
viability and retention, authors typically agree that vascularization, or the lack thereof, is
one of the primary limiting factors in TEC viability. Poor or slow vascularization imposes
a dimensional constraint on many engineered tissues, where thickness of tissue is
components is limited to under 100-200 um, or the purported diffusional limit of nutrient
and oxygen exchange.[42, 43] This limit is largely cited from a study that examined the max
distance of cells in mammalian tissue to a nearby vascular bed, but in reality, this
dimensional constraint is highly dependent on the cell type and the tissue composition.
For instance, engineered auricular cartilage and bone are tissues with acellular matrix
with a relatively sparse density of living chondrocytes and osteocytes that requires
minimal vascular support. Engineered bone and cartilage can arguably support larger
tissue dimensions; hence, the popularity of replacement therapy associated with these
tissues.[44] However, for many other soft tissues (e.g. skin or solid organ) this constraint
seems realistic, although experimental validation seems largely confined to 3D tumor
spheroid models.[45] To sustain larger tissue structures, an intact vascular pedicle,
constituting and inlet and outlet of blood flow into a perfusable capillary bed is needed.
Creating a vascular pedicle within implanted tissue is the ultimate target of vascular
tissue engineering and an intractable challenge for decades. When attempting to
decipher the rate limiting processes associated with vascularization of implanted tissue,
we noted a lack of a coherent step-by-step timeline of vascularization events associated
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with implanted tissue engineered constructs. This is surprising as this suggests that
much of the past efforts made to improve speed of anastomosis or vascularization of
TECs was not conducted with a systemic approach in mind and has not been built on
validated temporal or kinetic models. Authors would tune parameters such as cell type
(e.g. incorporation of pericytes) and availability of proangiogenic factors and examine
endpoints past a few days to weeks following tissue implantation.[46-49] This time scale
corresponds to host-driven implant vascularization. Host-derived microvessels can
invade an avascular implant as part of the foreign body response, but the process has
been reported to take at least a week.[50] Peri-implant neovascularization in such a
scenario typically proceeds shortly after formation of a fibrous capsule.[50] Unfortunately,
ischemic damage to tissues occurs within a time span of hours rather than days[19],
necessitating a focus on processes impacting vascularization within a 24 hour postimplantation window. A well-resolved temporal model, thus, should focus on this time
scale and illustrate dynamics of vascularization at early time points (hours to a few
days).

2.1.2 Avascular Graft versus Prevascular Tissue: Entry Points into
Vascularization Pipeline
Vascularization of an avascular tissue graft can be modeled by an ordered series
of events corresponding to angiogenesis in host animals (Figure 2.1), starting with
endothelial cell activation, network formation and ending with lumen formation, vessel
maturation, and perfusion of mature blood vessels.[51] The kinetics of each phase of the
vascularization pipeline can be explored by evaluating TECs that, by design, enter the
pipeline at different points.
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FIGURE 2.1: A temporal model of vascularization in TECs. Model accounts for the development
time associated with (1) endothelial cell activation, (2) migration of endothelial cells and
remodeling of the implant stroma, (3) Primitive network formation (4) anastomosis of
host/implant endothelial structures, (5) Network remodeling (6) Lumen formation within the
endothelial architecture, and (7) maturation of vessels through recruitment of mural cells. This
leads to formation of a blood-perfused vascular pedicle in an implant. Depicted is the expected
entry point of different implant types, with preceding development either occurring in vitro or
supplied by donor.

The field of reconstructive surgery provides useful terminology to describe the
spectrum of entry points. Restoration of damaged or dysfunctional tissue can either
involve transfer of tissue lacking blood flow, termed a graft, or transfer of a tissue
sustained by its own blood supply in the form of a vascular pedicle, termed a flap.[52]
Unique to current engineered grafts is the absence of any vascular architecture, forcing
them to enter the vascularization pipeline at the earliest time point. The unrealized goal
of tissue engineering is the formation of a true tissue flap, where the entire
vascularization pipeline can be completed in vitro, and perfusion can be established
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simply through microsurgical anastomosis of mature, perfusable TEC vessels to the host
vasculature. The graft-to-flap continuum is presented in Figure 2.1. In an ideal scenario,
we could develop grafts that partially advance through levels of the vascularization
pipeline and compare their progress through the remaining vascularization steps to
gauge the rate limits of each step in the pipeline. A more realistic simplification is to
compare two models: an avascular graft and a prevascular graft.
Prevascularization, or in vitro assembly of primitive endothelial networks
resembling a capillary bed, is one method of advancing an implant through the
vascularization pipleline towards a flap-like TEC design. The term prevascularization,
coined by Laschke and Menger, defines implants with capillary-like structures developed
in vitro.[53] Prevascular tissue should only need to insoculate to host branches rather than
initiate the entire process of angiogenesis. Angiogenic sprouting, while potentially faster
than de novo vasculogenesis, is still a slow process whereas inosculation, or merging of
microvessels into larger diameter vessels occurs very rapidly.[53] Specifically in vivo
microvessel growth by angiogenic sprouting occurs at a peak rate of 5 um/hr. [53, 54]
Spanning an entire implant exceeding dimensions of a few hundred micrometers at this
rate is too slow to prevent ischemic damage,[53] as hypoxia peaks in skeletal muscle at
approximately 8 hrs.[19] Creating implants in vitro with preformed vessels can vastly
reduce the distance an angiogenic sprout must travel to bridge the host and implant
vascular elements or shortens the entire process to direct inosculation.[55] In addition, a
preformed endothelial network has essentially completed the phases of extracellular
matrix remodeling and proteolysis characterizing the branching morphogenesis of the
vascular network.[56] Prevascularization approaches have been employed in past years
by growing an implant, such as artificial skin, around a host arteriovenous fistula that has
been extended to an externally located pocket, allowing angiogenic sprouts to permeate
the implant.[43] This surgical approach to forming a vascular pedicle ensures adequate
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vascularization of an implant, but has a limited practical application because the implant
must remained coupled to an immobilized host during its development. More recent
methods have involved co-culture of Human umbilical vein endothelial cells (HUVECs)
and mesenchymal stem cells (MSCs) to allow spontaneous formation of primitive
vascular network[57, 58];however, translational limitations exist with this technology. The
difficulty of regulating differentiation of MSCs as well as their potential tumorigenicity
limits the appeal of using these multipotent cells to develop a prevascular stroma.[59, 60]
Adipose microvascular cell -derived microvessels appear to be more stable than HUVEC
microvessels, suggesting that cell source is another means to improve engraftment
potential of endothelial/stromal cell cocultures.[61, 62]

2.1.3 Scaffold-Free Prevascular Endothelial Fibroblast and Fibroblast-only
Spheroid TEC Models
We have developed and previously reported on the anastomotic potential of a
scaffold-free prevascular implant model that is formed from the coculture of human
adipose microvascular endothelial cells (HAMECs) and normal human dermal fibroblasts
(NHDFs).[47] We use primary human adipose derived endothelial cells to ensure clinical
translatability, where an autologously derived population of cells can be re-implanted in a
patient with minimal morbidity due to immune compatibility complications. The adult
fibroblasts create the extracellular-rich stroma necessary to support a vascular bed and
provide additional proangiogenic stimuli. [63] A specific 1:4 ratio of human microvascular
endothelial cells and fibroblasts maximizes the density of endothelial cords when
allowed to self-assemble in a scaffold free nonadherent environment. Increasing the
density of fibroblasts resulted in endothelial clusters without cords, and increasing
density of endothelial cells resulted in structures lacking avascular stromal areas
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consistent with a vascular bed. [64] Within 3 days of in vitro culture in an agarose mold,
the coculture generated an extracellular matrix containing laminin, type I collagen, and
fibronectin. The interplay between ECM components, such as laminins and fibrillar
collagen, and cell surface integrins play a key role in vascular lumen formation.[65] Czajka
et al noted the presence of laminin throughout the ECM rather than constrained to the
basement membrane, as would be expected in mature blood vessels. This suggests a
more embryonic, primitive vascular network.[64] During the formation process, the
angiogenic potential of the SPEC implant also appears to change. Western blotting for
DLL4, a marker of endothelial tip cell phenotype showed increased levels at days 1 and
2 of SPEC incubation but decrease by day 3 when compared to control (avascular
fibroblast graph) (Figure 2.2). The fully formed implant is rod-shaped with in an
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avascular space composed of f-actin presenting fibroblasts and CD31+, VEGFR2, and
VE-Cadherin positive endothelial cells (Figure 2.3). Endothelial cells resembled loose,
filamentous cords (approx. 2-3 um thick) without an obvious hierarchy of larger and

FIGURE 2.2: Western Blot of vascular markers VEGFR2, VE-cadherin, vWF, and DLL4 of SPEC
and FOS during in vitro assembly. GAPDH house-keeping protein functioned as the loading control.
Anti-Dll4 blotting corresponding to endothelial tip cell phenotype was tracked across day 1, 2, and
3 of SPEC and FOS growth. Relative optical density was calculated by normalizing to FOS day 3
controls. Ratio of relative optical density for DLL4 to the relative optical density of GAPDH is
displayed (n=3). Dll4 peaks at D2 and decreases at D3 which is similarly reflected by VE-cadherin
western blot. This suggests a period of quiescence after two days incubation of the SPECs. VEGFR2
and vWF, markers of endothelial cells, remain stable after reaching a peak at D2, suggesting limited
endothelial cell proliferation at D3.

smaller vessels. The microvessel area fraction of the implants, or percentage of implant
occupied by endothelial structures prior to implantation, was approximately 28 ± 13%,
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FIGURE 2.3: (a-c) Whole-mount immunofluorescence image of rod-shaped scaffold free prevascular
endothelial fibroblast construct (SPEC) liberated from 2% agarose mold. F-actin fibers present in
fibroblasts labelled with Phalloidin 488 (green) represent the stromal components of the implant, and
CD31-labeled structures (red) represent capillary-like cords of endothelial cells. (d,e) Whole-mount
immunofluorescence images of rod-shaped fibroblast-only spheroids (FOS) similarly presented with Factin fibers in fibroblasts labelled with Phalloidin 488 (green). However, these constructs lack presence
of CD31-labeled structures (red) (f) Light microscopy images of Hematoxylin and Eosin stained rat
hind limb tissue sections (10 μm) containing cross section of implanted SPEC (encircled) between
vastus lateralis and biceps femoris muscles.

ranging between a third and a fourth of the total implant volume. Mature endothelial
cells, while capable of forming spontaneous capillary like tubes in vitro, appear to require
consistent input of proangiogenic environmental signaling. Fibroblasts, through
constitutive expression of vascular endothelial factor (VEGF), basic fibroblast growth
factor (bFGF) and angiopoitin-1 (Ang-1), address this basic need.[63] The presence of
fibroblasts corresponds to an increased microvessel density within an implant and
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stabilization of vessels by signaling endothelial cell to express smooth muscle actin. [57]
Other ECM proteins deposited by the fibroblasts such as laminin, collagen type I and
collagen type IV are typically needed for vessel maturation, suggesting a possible role
for the mixture the terminal phases of the vascularization pipeline.[51] The presence of a
solid, fibroblast-derived ECM does not appear to severely limit the mobility of endothelial
cells following the 3-day incubation period. A time-series image of GFP-tagged HAMECs
within the SPECs placed on a tissue culture plate demonstrated a high degree of motility
of the endothelial cells following three days of culture, with some cells tracked as
traveling over 400 μm in distance within a 24h time series (Figure 2.4).

The SPECs retain a set of properties that could have inherent therapeutic value
when incorporated into replacement tissue technologies. SPEC spheroids can readily
fuse to form larger constructs in unconstrained nonadherent conditions and can reshape

FIGURE 2.4: SPECs with GFP-tagged HAMEC endothelial cells were placed within on a 35-mm
dish. Plates contain a monolayer of fibroblasts with an exclusion region created by placement of
silicone disc. SPEC were placed within this exclusion zone and imaged using Lionheart Fx live cell
widefield microscope. Endothelial movement to and from implant exterior was tracked for three
days. The time series depicted includes Day 2 0h to Day 3 0h. Magnitude of net displacement vectors
were calculated, with an average displacement of 247 μm within a range of 62-494 μm.
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their cytoskeletal structures to assume patterns dictated by confinements such as an
agarose mold.[34] This scalable and shapeable nature, coupled with the primary
endothelial cord networks of the SPECs make them ideal analogues to a vascular
stroma or artificial vascular bed that is inherent to the function of most tissues. The
SPECs can readily incorporate renal segments[66] and pancreatic islets[26], paving the
way for rapidly vascularizable artificial renal grafts and bioartifical pancreas. To make
these technologies a reality, however, we must first identify processes that speed or
hamper anastomosis and perfusion of implanted grafts.
Removing the microvascular endothelial cell fraction from the SPEC model, we
are left with a fibroblast-only spheroid (FOS). While SPECs presented with cord like
structures positive for vWF, VEGFR2, and VE-cadherin (Figure 2.3), FOS implants
displayed negligible levels of these vascular markers. They do not condense as much as
SPECs while forming in agarose molds. We contrast the vascularization behavior of
these avascular graft-like fibroblast spheroid and vascularization of our more flap-like
prevascular implant model, offering two different points of entry into our proposed
temporal model of vascularization. The SPEC model permits examination of the
transition from primitive network to a complex ordered anastomosed network.
Specifically, we hypothesize that the existing self-assembled primitive network of the
SPECs allow earlier host-implant anastomosis and increased presence of lumen
containing vessels in the interior of the implants by 24h compared to avascular grafts
such as fibroblasts spheroids.

2.1.4 Using SPECs and FOS to study In Vivo TEC vascularization dynamics
SPECs, fibroblast-only spheroids (FOS), and silicone implants were implanted in
54 Sprague Dawley rats and harvested at 6h, 12h, and 24h (n=5 per time point and
implant type). Silicone implants were included in the study in order to discriminate
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between host response to cellular and acellular material. Due to our choice of an
immunocompetent rat host model, and human cells, the silicone implant study also
indirectly helped us partially rule out a xenobiotic response when vascularization events
were observed around both the silicone and cell-based implants. The implanted
constructs were localizable within the rat submuscular pockets by the cell tracker in
immunofluorescence images and seen as basophilic regions within the eosinophilic
musculature in hematoxylin and eosin images. Pinch-marks made by forceps were used
as fiducial points to localize implant during sectioning (Figure 2.3).
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All three implant types developed a CD31 and vWF-positive capsule as early as
6h post-implantation, indicating early endothelialization of the host-implant interface
(Figures 2.5, 2.6). The SPECs showed this capsule interdigitating with internal vascular
elements at 6h; however, neither the FOS, nor the silicone showed endothelial cords
within the implant interior at the 6h time point. By 12h, the SPECs displayed larger
vessel-like bands composed of smaller cords penetrating through the implants, some of
which bisected the implants (Figure 6a). By 24h, many small lumen-like structures were
present at the periphery of the implant connecting with the thicker endothelial capsules

FIGURE 2.5: (a) Endothelial reorganization within TECs was imaged through
immunofluorescence imaging with Hoechst nuclear stain (Cyan) and anti-CD31 antibody
stain for endothelial cells (Red). A capsule-like layer of endothelial cells surrounds both
construct types at 6h. The internal endothelial structures in the SPEC interdigitate with this
capsule, resulting in a lacy layer of cords. By 12h, coalesced bands of endothelial cords
penetrate SPEC interior, while fibroblast spheroids still lack internal endothelial structures.
At 24h, both fibroblast spheroids and SPECs are invaded by endothelial cords, with SPECs
containing a more complex branching structure at the implant/muscle interface. (b)
Cd31+structures(red) with apparent lumens are visible within implanted SPEC cells labeled
with Cell Tracker (Blue) at 12h post-implantation. (c) Invading von Willebrand factor+
endothelial branches from the endothelial capsule inosculate with cell tracker positive
endothelial cords (magenta) indicating both host and implant contribution to SPEC vascular
network.
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(Figure 2.5a). Penetrating cords within the SPECs colocalized with the cell tracker
(Figure 2.5c), indicating implant contribution to these endothelial structures.
The internal vasculature of the SPECs was largely implant derived, as indicated
by the monoclonal human CD31 stain (Figure 2.6). By contrast, the endothelial capsule
components in the SPEC and FOS only express polyclonal vWF, which labels both rat
and human endothelial cells, indicating derivation from the rat hosts. Vessels in control

FIGURE 2.6: (a-c). Monoclonal anti-human CD31 antibody stain (red) and polyclonal anti-vWF
antibody stain (green) colocalize in implant-derived human endothelial structures (yellow). These
structures are limited to the interior component of the implanted SPECs at both 6h and 24h. Hostderived vascular networks only stain for anti-vWF stain and are visible at the external capsule
surrounding the SPECs and in vessels distal to the implant site in the opposite host hind limb muscle.

sections of muscle without a surgical pocket similarly solely express vWF in their
lumens. The SPECs displayed SMA+ puncta indicative of pericyte involvement [67] as
early as 6h, with vessel-like patterns matching vWF expression on sister sections by 12h
(Figure 2.7).
Cells within both FOS and SPEC continued to die between 6 to 24h as
evidenced by increased TdT dUTP Nick-End Labeling (TUNEL+) staining for apoptotic
and necrotic cells (Figure 2.8). There was no significant difference between FOS and
SPEC survival at 6h-24h. This corresponds to a lack of evident injected dye perfusion of
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vessel lumens within the 24h window despite presence of red blood cells in SPEC
implants from tissue harvested at 24h (Figure 2.9).

FIGURE 2.7: Immunofluorescent images of tissue sister sections (10 um apart) demonstrate
presence of αSMA+ (Yellow) cells in regions presenting with vWF+ vessels with apparent lumens
(red) 12 hours post-implantation. This is consistent with recruitment of αSMA+ pericytes or vascular
mural cells expected during vessel maturation. SMA+ expression at 6h post-implantation is less
consistently associated with vascular development, with few tubule-associated SMA+ cells.

The timeline of vascular events (Figure 1) immediately following implantation of
prevascular tissue is crucial to evaluating the technology. The observation windows
selected in this study were designed to dissect the components of endothelial
organization, cord sprouting, anastomosis, network remodeling, lumen formation and,
ultimately, vessel maturation that occurred early in the in vitro development of our
implant and shortly following implantation. The 6-12h post-implantation window is
particularly important as it contains the time points associated with a peak in markers of
hypoxic stress found within autologous full-thickness muscle flap transplants in prior
studies by our laboratory.[19]
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FIGURE 2.8: SPEC and FOS sections (10um) harvested at 6, 12, 24h were stained with Tdt dUTP
Nick-End Labeling Assay (green) and counterstained with Hoechst nuclear stain (blue). A
significant increase in TUNEL+ cells was observed between 6h and 24 h for FOS and SPEC
implants (n=4, p<0.01) compared to the surrounding rat host muscle.

2.1.5 In vitro SPEC development was consistent with nonrandom organization
of a proangiogenic vascular network
The endothelial cord formation within the SPECs is a nonrandom process, with
the initial dispersed endothelial cells coalescing into cords throughout the 3-day
incubation period. This migration stands contrary to the popular theory of cellular
behavior termed the differential adhesion hypothesis.[32] If the rearrangement was
entirely driven by passive cell adhesion behavior rather than active vascular
development processes, a single interface between endothelial cells within the core and
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fibroblasts on the periphery would be observed. This behavior would optimize interfacial
energy based on cell-type specific expression of adhesion molecules such as
cadherins.[33] Further evidence of active vessel formation within the implant is provided
by western blot data, through expression of vascular markers such as VEGFR2, VEcadherin, and vWF. Dll4 expression in implants is consistent with angiogenic and
anastomotic potential of endothelial cells as reported in literature.[68, 69] The upregulation
of DLL4 expression in SPECS at D2 is consistent with increased vascularization of the
implant; in contrast, the comparative downregulation at D3 of incubation, coinciding with
when the implant finishes resolving into a solid structure, is consistent with quiescence
of the prevascular networks. This period of quiescence may contribute to the latency

FIGURE 2.9: Rat hosts were prepared for perfusion 24 hours post-implantation. Hosts were
perfused with DiI lipophilic membrane stain (120 ug/mL in PBS with 5% glucose) following
puncture of the left ventricle at a rate of 2 mL per minute. DiI-perfused vessels were seen through
confocal microscopy (purple). The implants were visualized by Deep Red Celltracker (blue).
Vessels in the muscle tissue surrounding the implants (a) and distal to the implants on the opposite
host hind limb (b, c) were clearly labeled with DiI. DiI successfully perfused and stained vessels of
arteriole/venule (100-300 μm) diameters (b) or capillary (5-10 μm) diameters (c). (d-e) Hematoxylin
and Eosin stains of implants harvested at 24h, however, contain red blood cells and evidence of
leaky appearing vasculature.

between anastomosis and in vivo tubulogenesis. While ideally anastomosis of
prevascular implants should only involve inosculation of externally located cords to the
nearby host vasculature, the need to ramp up the angiogenic machinery of the construct
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cells might delay further morphogenesis of these tubes and delay perfusion through the
resulting networks.

2.1.6 Early 6hr post-implantation period demonstrates rapidity of endothelial
capsule formation around implants, and rapid inosculation of scaffold-free
prevascular constructs to host
One of the major goals of vascular tissue engineering is near instantaneous perfusion of
well-organized cords either by spontaneous in vivo inosculation or surgical
anastomosis[42]. While these constructs were not well perfused during the 24h
observation time (Figure 2.9), endothelial structures extended continuously from the
host to the interior of the SPEC implants within 6h, indicating rapid mobilization of
endothelial cells to and from the implant. Notably, the SPEC internal structures are
derived from human endothelial cells (Figure 2.6), suggesting that this anastomotic
network contains, at least in part, the preformed primitive network that was developed in
vitro.
Additionally, the microvessel vascular area of the SPECs 6h post-implantation is
26±5% which is comparable to the vascular density of the implant prior to implantation
and only approximately 1.2-fold lower than the average microvessel vascular area
fraction throughout the 24h time point. The filamentous net-like primordial form of the
network prior to implantation is preserved at 6h post-implantation, with a high branch
point density of approximately 1.2x105 per mm2 implant tissue, resembling the preimplantation average branching density of 1.12x105 per mm2. The FOS, on the other
hand, show a significantly lower presence of branching endothelial structures within the
implant stroma, with most of the 8 ± 3% microvessel area confined to the external
capsule. As such, the fraction of the vascular area that includes internally penetrating
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tubules in the SPEC is 4.7-fold higher than the fraction within fibroblast-only spheroids.
Surprisingly, endothelial capsule formation occurs around our silicone-based implant,
suggesting that the mobilization and reorganization of endothelial structures might be
driven by recognition of a foreign body- interface more so than communication with the
living cells of the implant. The silicone implant displayed essentially no visible
microvessels within its interior during the 24h observation window.

2.1.7 The 6 to 12-hour window shows increase in microvessel area in fibroblast
only spheroids and silicone implants but not in SPECs; SPECs show
remodeling and fusion of existing branches
The 6-12-hour window is a period of remodeling in both the SPEC and FOS implant
models. Notably, the band of host-derived endothelial structures around the implant
appear to thicken with a small but significant increase of internally penetrating branches
within some of the FOS. However, the mean microvessel area of the fibroblast
spheroids, including the capsular components, remains 3.2-fold lower than the SPEC
implants and comparable to that of the silicone implants. In other words, the lack of an
existing internal endothelial network in the FOS results in a 12 hour latency in vascular
development of these implants compared to SPECs. The SPECs, on the other hand,
maintain a nearly constant mean vascular area; however, there is a 1.5-fold decrease in
junctions within the implant and a 2-fold decrease in junctions within the endothelial
capsule. This may be attributed to increased condensation of endothelial branches to
larger structures, an example of which is seen in (Figure 2.5), where a denser band of
endothelial structures appears to pass through the center of the implant and lumen like
structures begin to appear within the SPEC implant cross sections. This cohesion of
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existing endothelial cords to form larger multicellular structures is most consistent with
formation of the early vascular tree during embryological vasculogenesis.[70]

2.1.8 Parity between SPEC and FOS angiogenic development by the 24-hour
timepoint
By 24h, SPECs and FOS begin to resemble each other in terms of endothelial
organization and mean vascular area, with a greater preponderance of penetrating
endothelial cords in the fibroblast- only spheroids than at previous time points. The
advantage in anastomosis provided by the SPECs, thus, seems to lessen at the 24h
time point, as cords from the peripheral endothelial capsule appear to reach the center
of the FOS. This rapid invasion of vessels in a previously avascular space is itself a
surprising finding. Vascular network can invade on its own as a part of foreign body
response, but the process has been cited to take a few days to a week.[42]. The presence
of a branching vascular architecture, however, still seems largely limited to the SPECs.
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FIGURE 2.10:(a) Implant vascular structures (CD31 or vWF+) were segmented based on
immunofluorescent images of tissue cross sections (10 μm depth) containing the entire implant cross
section as well as an intact muscle/implant interface. Endothelial structures in direct connection with this
interface and the endothelial capsule surrounding the implant were segmented separately (green) from
the vascular structures found within the interior of the implants (yellow). (b) Total microvessel area
fraction, or the percentage of the implant cross sectional area containing vascular elements, was calculated
for each implant, with comparisons made between implant types at the 6h, 12h, an 24h time points. (c)
Microvessel area fraction excluding the endothelial capsule at the muscle/implant interface was calculated
for each implant. (d) The fraction of endothelial cords that penetrate the implant interior was calculated
by dividing the length of the cords found excluding the capsule vessels by the total length of the vascular
network. This fraction is a surrogate marker of the invasiveness of the vessels within and surrounding
each implant within the host. (e-f) Junction density was calculated as the number of vessel branch points
found per um2 of the implant cross sectional area. Similarly branching density was calculated as the
number of branches per um2. These two metrics assess the branching complexity of the developing
vascular networks in each implant type across time. Microvessel area, junction density, and branch
density of SPECs remain significantly elevated compared to other implants at all time points. Fibroblast
spheroids demonstrated the most growth in terms of microvessel area and penetrating tubule fraction
between 12 and 24h with branch density resembling the SPECs at 24h. * statistically significant difference
(p<0.05) between implant type and SPEC. ** statistically significant difference (p<0.001) between
implant type and SPEC

2.1.9 Evidence of maturation of SPECs at 12-24-hour without perfusion
In angiogenesis, maturation of vessels follows anastomosis and usually occurs
concurrent with perfusion of vascular networks. [71] However, in the absence of
consistent perfusion, the SPECs show some indication of vessel maturation. Smoothmuscle actin presenting cells, representing mural, stabilizing cells such as pericytes
around capillaries, or smooth muscle cells around larger arterioles and arteries, are
recruited in the latter stages of angiogenesis, involving a careful interplay between
basolateral elements of endothelial cells such as Tie-2, macrophages, and pericytes.[72,
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The SPECs, which present with an apparently disorganized SMA+ cells at the early

6hr time points show SMA+ cells more fully organized around lumen like structures in
the SPEC at the 12 and 24 hour timepoints (FIGURE 2.7).
Perivascular organization alone, unfortunately, does not translate directly to
improved vessel patency, as evidenced by poor dye perfusion and leaky vasculature
within the implant at 24h (Figure 2.9). Additionally, both the SPECs and Fibroblasts lose
approximately 13-14% of their inner cell mass (<4% dead cells at 6h to 17-18% at 24h
post-implantation), without a statistically significant improvement of cell survival in the
SPECs at this time point. Improved survival and functional recovery of implanted tissue
will depend on specifically addressing rate limiting steps, both spatially and temporally,
at the host-implant interface.

2.2 Computational Control Flow Model of TEC Vascularization
We are left with 3 crucial questions following our study of in vivo vascularization of
SPECs and fibroblast-only spheroids:
(1) Why do the SPEC prevascular cords lack consistent blood perfusion at 24 hours
post-implantation?
(2) Why does the SPEC design only confer a temporal advantage in vascularization
during the 0-12h window?
(3) What is the actual rate limiting step in the vascularization pipeline?
One of the crucial misapprehensions propagated in literature is that endothelial migration
is a crucial limiting factor in angiogenesis during wound healing and implant
vascularization. This may be due to a focus on in vitro tube formation assays, where
cord development is modeled as a pattern of endothelial proliferation and migration.[74]
Our data, however, suggests that recruitment of endothelial cells to an implant interface
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and even a sham wound pocket is nearly instantaneous, occurring within 6 hours of
insult. In order to identify processes that limit vascularization in our TEC models in vivo,
we would need to develop TEC models that progress past the primitive SPEC
microvasculature. To our knowledge, there are no established scaffold-free models to
represent lumenization of endothelial cords, although we have attempted various
methods of improving lumen formation of SPEC cords in vitro (explored in Chapter 3).
On the other hand, we have another avenue available to us other than continued in vitro
and in vivo experimentation. In silico experimentation and computational modeling of
physiological phenomena can augment our experimental observations. While not a true
substitute to in vivo or in vitro studies, computer models can be very useful in generation
of hypotheses and provide a logical framework through which we can plan further
experimentation. The main stipulation is that care is taken to ensure that each
mathematical or computational approach fairly represents biological realities. This can
be achieved by integrating models that have already been independently validated at
cellular or molecular levels into a multiscale model that produces insight into tissue
formation behavior. Such approaches are similar to those employed in systems biology,
especially in those pertaining to multiscale phenomena such as angiogenesis.[74]
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FIGURE 2.11: Both Fibroblast spheroids and SPECs can be modeled as cylindrical implants
sandwiched between two skeletal muscle interfaces, the vastus lateralis and the biceps femoris
muscles. The geometries can be further simplified to a slab of tissue sandwiched between two
interfaces. Within the implant, various differential equations contribute to modeling of VEGF
accumulation, endothelial cell infiltration (as measured by changes in microvessel density), and
oxygenation (the marker of adequate vascularization). The interfaces supply the boundary
conditions (VEGF secretion from skeletal muscle, physical source of endothelial cells, fully
oxygenated tissue within the skeletal muscle itself).

We start first with a deterministic model, where no randomness of data is
considered, and vascularization is described by the solution to a set of ordinary
differential equations. To do so we consider a diagram of our implant (SPEC or FOS) as
it vascularizes in a muscular pocket (Figure 2.11) which shows the cross section of one
of our TEC rods sandwiched between two interfaces of skeletal muscle tissue.
Vascularization of both FOS and SPECs occurs at this interface, with host-derived cords
invading into implants. The skeletal muscle interface, thus, provides both the source and
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boundary conditions for the signal representing implant vascularization. As indicated by
the block diagram of our simulation, we model vascularization as the interplay of
proangiogenic factor accumulation, endothelial cell infiltration, and tissue oxygenation
within our implants. Physioxic levels of tissue oxygenation is our ultimate marker of
adequate vascularization, while proangiogenic factor accumulation and endothelial cell
infiltration contribute to this process. We focused on these two phenomena as the
drivers of vascularization as this allowed us to combine insights gained from literature
regarding the role of the chief proangiogenic factor VEGF with our in vivo findings
addressing the impact of prevascularization. The following sections focus on the ordinary
differential equations associated with each block of our modeling framework in Figure
2.11. Parameters used in this model are summarized in (Table 2.1).
Table 2.1: Parameters used in Simulink Simulation
Parameter
Diffusivity of VEGF-A

Value

Source
104 μm2

Physiol 102, 2007.[75]

(VEGF-164)
Basal VEGF secretion

0.25 x 10-17 pmol∙s/μm-2

30.3% (stroma of SPECs)

Pattanaik et al., Biores
Open Access, 8:1, 2019[76]

fraction
VEGF EC-50 (regarding

Gabhan et al., J App
Physiol 102, 2007.[75]

from skeletal muscle
Max endothelial volume

Gabhan et al., J App

20 ng/mL (we calculated

chemotaxis)

Poldevaart et al., J Control
Release, 184, 2014

We use Simulink®/MATLAB, a graphical block diagraming tool that allows to map our
sets of differential equations as a series of transfer functions with conditional statements
and thresholds that inform us when an ideal condition (i.e. physioxia) is attained.
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Specifically, MATLAB is employed to evaluate the simultaneous solutions to the set of
differential equations that would otherwise be difficult to evaluate analytically.

2.2.1 3.2.1 Modeling VEGF Diffusion through the implant
Vascular Endothelial Growth Factor (VEGF)-A, specifically isoforms VEGF-164 in
rodents and VEGF-165 in humans, diffuses readily through connective tissue and
interacts with Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) as a principal
mediator of most angiogenic processes.[77] The specific cell-signaling processes
implicated by this interaction are explored in Chapter 4. Fick’s 2nd law of diffusion is
used to model VEGF diffusion through the core of the implant. This is generally
formulated as:
𝜕𝐶
𝜕𝑡

= 𝐷∇2 𝐶,

In other words, the change in concentration of a freely diffusible molecule like VEGF-A at
a point in the implant is proportional to the second derivative of it is distribution in space.
By focusing on a slab of tissue between two interfaces, we simplify this equation to
𝜕𝐶
𝜕2𝐶
= 𝐷 2,
𝜕𝑡
𝜕𝑥
where x is increasing depth from the implant-muscle interface. This simplification is not
entirely appropriate, as the SPEC rod is a cylinder. Our boundary conditions, two
interfaces with changing concentration fluxes, can make working with cylindrical
coordinates a little complex and necessitates a 2D partial-differential equation solution.
For computational facility, we focused on the 1-D slab model (Figure 2.11); thus, VEGF
diffusion and the entire control flow model more faithfully recapitulates behavior in a line
running through the rod -shaped implant perpendicular to the interfaces. OneDimensional second partial derivatives in space were calculated by maintaining a vector
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at each point in an implant that tracked spatial distribution of concentration at
neighboring points. Concentration values were updated using the centered finite
difference method, similar to a method employed by Ahmed et al.[78]:
𝑛
𝑛
𝐶𝑖𝑛+1 − 𝐶𝑖𝑛
𝐶𝑖+1
− 2𝐶𝑖𝑛 + 𝐶𝑖−1
=𝐷
,
∆𝑡
∆𝑥

The indices n and i track time steps and position steps, respectively. One final
simplification in this component of our model is the choice to model diffusivity as
unchanging in time and space. The corresponding Simulink ® block is depicted in
(Figure 2.12).
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FIGURE 2.12: Simulink Block Diagram of VEGF diffusion. Inputs are oxygen tension and a vector
of adjacent VEGF concentrations at specific depth in the 1-D slab simplification of the implant.

Laplace ቊ

®

𝑛
𝑛
𝐶𝑖+1
− 2𝐶𝑖𝑛 + 𝐶𝑖−1
,ቋ
∆𝑥

Governing Equations
For VEGF Diffusion
2.2.2 Modeling Endothelial Cell Infiltration of TEC

While recruitment of endothelial cells to the implant interface is rapid, invasion of
endothelial cords into the implant stroma is a slower process, demonstrated by the 1224h latency in fibroblast-only spheroid vascular cord development. Using the
39

microvessel area fraction versus time data attained through our in vivo experiments and
prior literature associated with endothelial and macrophage infiltration, we can contribute
a block to our in-silico control flow model of TEC vascularization.
Much of the literature pertaining to endothelial infiltration into tissue examines
tumor angiogenesis models. Cai et al model endothelial movement in a tumor
microenvironment and extracellular matrix as follows[79]:
𝜕𝑒
= 𝐷𝑒 ∇2 𝑒 − ∇ ∙ (𝜑𝑖𝑛𝑓𝑖𝑙𝑖𝑡𝑟𝑎𝑡𝑖𝑜𝑛 𝑒∇𝐶𝑉𝐸𝐺𝐹 + 𝜑ℎ𝑎𝑝𝑡𝑜𝑡𝑎𝑥𝑖𝑠 𝑒∇𝐶𝑀𝑎𝑡𝑟𝑖𝑥 ),
𝜕𝑡
The term e refers to the endothelial density at a position in the tissue of interest. The
𝐷𝑒 ∇2 𝑒 resembles Fick’s law of diffusion and looks at random motility of endothelial cells.
While we can observe this phenomenon in vitro, with Brownian movement of endothelial
cells, the actual distance traversed is small, so we exclude this term from our model. The
remainder of the equation relates endothelial density changes to a chemotaxis
component proportional to the VEGF concentration gradient and a haptotaxis
component proportional to the matrix density gradient. While modeling the effect of
matrix density changes would be highly pertinent to scaffold-free tissue development, we
focus on the relationship between endothelial infiltration to an existing VEGF gradient.
This links endothelial infiltration to our VEGF diffusion model block. What we are left with
is:
𝜕𝑒
= −∇ ∙ (𝜑𝑖𝑛𝑓𝑖𝑙𝑖𝑡𝑟𝑎𝑡𝑖𝑜𝑛 𝑒∇𝐶𝑉𝐸𝐺𝐹 ),
𝜕𝑡
To derive the infiltration coefficient, 𝜑𝑖𝑛𝑓𝑖𝑙𝑖𝑡𝑟𝑎𝑡𝑖𝑜𝑛 , we look at prior work by Lemon et al
modeling macrophage infiltration into tissue[80]:
𝜕𝐶𝑚𝑎𝑐𝑟𝑜
= 𝛼𝛾(𝜃𝑚𝑎𝑥 − 𝐶𝑚𝑎𝑐𝑟𝑜 )𝐶𝑣𝑜𝑖𝑑 𝑠𝑝𝑎𝑐𝑒 − (𝑑𝑒𝑎𝑡ℎ 𝑟𝑎𝑡𝑒),
𝜕𝑡
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The equation itself simplifies to the product of constants associated with a tissue’s
inherent capacity to support infiltration (𝛼), a cell’s inherent invasiveness (𝛾), and the
available amount of void spaces that can be occupied by cells. Macrophage invasion is
limited by 𝜃𝑚𝑎𝑥 , a theoretical max allowable concentration of cells in the tissue. This
closely approximates our own findings when comparing SPEC and FOS microvessel
densities over 24h. Between 12h-24h, the SPECs’ microvessel density appears to
saturate as invading cords occupy available space in the matrix. Combining the
concepts underpinning these two equations, we model endothelial infiltration as:
𝜕𝑒
𝛾
𝐶
(E
− 𝑒),
= { 𝑐𝑜𝑛𝑠𝑡𝑎𝑛𝑡 𝑉𝐸𝐺𝐹 𝑚𝑎𝑥
0,
𝜕𝑡

𝑒 < E𝑚𝑎𝑥
𝑒 ≥ E𝑚𝑎𝑥

The endothelial infiltration is functionally linked to the VEGF gradient calculated in the
VEGF module (Figure 2.12). E𝑚𝑎𝑥 was set at 30.3% based off our previously published
in vivo findings.[76] The 𝛾𝑐𝑜𝑛𝑠𝑡𝑎𝑛𝑡 was ultimately determined by a combination of mapping
endothelial response to dose response curves evaluated in literature[81], and varying the
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constant to match the vascularization dynamics noted in our FOS and our SPEC

®

Modeling Infiltration
of ECs

FIGURE 2.13: Simulink Block Diagram of Endothelial infiltration. The input is the VEGF
concentration evaluated at a particular depth.

implants. EC-50 is noted at 20 ng/mL, which we to translate to 5 x 10-5 picomoles/um in

our 1D model assuming a 1 mm by 1mm cross section of our implant). Given the
relatively low levels of VEGF released from skeletal muscle interfaces, we should never
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be at a point where we have more VEGF available than the EC-50 concentration (we
expect a peak at the interface of 3.5 x 10-15 picomoles/um); hence our linear relationship
between VEGF gradient and endothelial response. The corresponding Simulink ® block
representing endothelial volume fraction changes is depicted in (Figure 2.13). This
module allows us to link our own insights into tissue vascularization into the final
multiscale model.

2.2.3 Modeling Boundary Conditions and Tissue Oxygenation
The skeletal muscle-implant interface module derives much of its validation from
Gabhan et al, who measured and modeled release of VEGF from the skeletal muscle
extra-membranous compartment in the context of oxygen demand.[75] They determined
that without accumulation of a VEGF store, diffusion and plasma/tissue removal of
VEGF would result in too little VEGF at steady-state to induce angiogenesis.
Additionally, their model of interfacial release of VEGF provides an intuitive link between
secretion of VEGF and tissue oxygen levels:

𝑆𝑉𝐸𝐺𝐹

𝑆𝐵𝑎𝑠𝑎𝑙 ,
20 − 𝑝𝑂2
= 𝑓(𝑝𝑂2 ) = {𝑆𝐵𝑎𝑠𝑎𝑙 × [1 + 5 × (
)] ,
19
6 × 𝑆𝐵𝑎𝑠𝑎𝑙 ,

𝑝𝑂2 ≥ 20 mmHg
1 mmHg < 𝑝𝑂2 < 20 𝑚𝑚𝐻𝑔
𝑝𝑂2 ≤ 1 𝑚𝑚 𝐻𝑔

𝑆𝐵𝑎𝑠𝑎𝑙 represents the basal secretion of VEGF in scenarios that are nearly physioxic
(Table 2.1), while 𝑆𝑉𝐸𝐺𝐹 is the VEGF injected into the implant boundary as a function of
apparent oxygenation of the interface. The above piece-wise equation generates a
constant flux boundary condition with 3 control points (where particular levels of
oxygenation changes boundary flux) as well as our initial condition, where the partial
pressure of oxygen at the interface is set to 0 mmHg.
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2.2.4 Combined Model
We can model oxygenation (Figure 2.14) as a product of VEGF availability in the
implant and the endothelial infiltration, with a constant (K) that acts as a “gain” in the

Vascularization/

Partial Pressure of O2

®

FIGURE 2.14: Simulink Block Diagram Oxygenation at an implant interface.
Vascularization/Oxygenation block is a function of inputs from the endothelial
infiltration block (input 1) and VEGF concentration simulation block (input 2)

44

FIGURE 2.15: Simulink Block Diagram of 1-D TEC Vascularization. Vascularization at the muscle/implant inteface is
modeled by boundary conditions (blocked in dashed lines), while the implant interior is modeled components sandwiched
between this interface

®

®

Simulink TEC Vascularization Model

control flow diagram, amplifying the contribution of either the VEGF component or the

endothelial infiltration component. If this appears arbitrary, this is because our constant
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K is selected in order to approximate our in vivo observations. We do not actually see
consistent blood perfusion of our implants until 72h post-implantation (Figure 2.10). The
computational model approach to simulating oxygenation, our surrogate marker of
vascularization, allows us to compare the kinetics of VEGF accumulation and endothelial
infiltration. We select a termination criterion for our model as when the tissue attains an
apparent 5% oxygen (38 mmHg), or physioxic levels of oxygenation. Physioxia is more
relevant to peripheral tissue than apparent “normoxia”, which is usually set at 20%
Oxygen.[82] (Figure 2.16) shows a representation of VEGF accumulation, microvessel
(endothelial) density in an implant, and ultimately implant oxygenation in a fibroblast-only
spheroid, where the initial microvessel density is set to 0. The most important findings
from this modeling approach are the illustration of which time domains for each model
block contribute to tissue oxygenation. While, microvessel area fractions at the implant
boundaries saturates early within 24-48h, VEGF accumulation at the interface at this
point is within 10-15% the amount accumulated by 3-days. The existing VEGF gradients
throughout the implant are also very small; while external forces, such as injury might
drive endothelial cells to the interface of an implant, there does not appear to be much of
an impetus for cells to penetrate through the implant interface. On the other hand,
oxygenation appears insensitive to microvessel area fraction changes after 24h,
reconfirming one of our main concerns with our prevascular model. We can design a
TEC to have an ideal prearrangement of endothelial cells, but the cells themselves may
lack the necessary proangiogenic factors to continue to progress through the
vascularization pipeline. In fact, as demonstrated in Figure 2.2, the SPECs demonstrate
a reduction in endothelial cells expressing tip cell phenotype after reaching a peak at 2days of incubation in vitro. Thus, we consider modifications of our TEC designs the
Chapter 3, where we improve the availability of proangiogenic factors, with a major
focus on models that focus on VEGF pre-dosing.
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2.2.5 Limitations and Conclusions
The key mystery that remains after assessing the microvessel network in the SPECs is
their lack of apparent patency. Our Simulink® reveal that the lack of adequate
proangiogenic signaling is a possible limitation in our prevascular model. During our
experiments, few RBCs were found within the implants during our 24-hr observation
window, and DiI perfusion of the Rat vasculature led to little dye retention within the
implants. This is despite the apparent systematic progression through the key phases of
angiogenic development: endothelial migration and reorganization, anastomosis to host
vessels, and maturation through recruitment of mural cells. As previously suggested,
stable inosculation still involves angiogenic activation of the cords and microvessels of
an implant.[53] Mobilizing the angiogenic molecular machinery might result in a
pronounced latency between apparent inosculation of host and implant vessels and the
formation of a contiguous, patent lumen. Physical contact of host and implant endothelial
structures does not guarantee patency. Lack of fluid flow during culture conditions might
be an important practical limitation to tubulogenesis or proper lumen formation in the
primitive endothelial networks of the SPEC. Mechanical strain and shear stress have
been shown to aid in tubulogenesis and vessel diameter increase in vitro.[61, 83] Static
conditions in the incubation of the cells might have resulted in endothelial cords that
were otherwise unequipped to handle bulk fluid flow through the structures.
Viability of the constructs is also impacted by the nature of their design. Several
SPECs and fibroblast only spheroid presented with a lower density region towards the
center of their cross-sectional area, a facet carried over from their in vitro composition
(visible in Figure 2.3). This is a major limitation of the scaffold-free engineering process,
as a high-density cell suspension is required to form the contacts necessary to develop
the 3d construct. High cellular densities can act as a barrier to adequate exchange of
nutrients and oxygen at the core of the constructs. This likely artificially increased the
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size of the avascular space at the core of the implanted constructs. An alternate
explanation of this avascular space is also discussed in Chapter 4, where cell sorting
behavior might drive this compartmental segregation of microvascular and avascular
spaces. Ultimately, translation of this technology may be hampered by some notable
limitations involved in using human adipose-derived endothelial cells. This arises from
the need for a partially invasive biopsy to collect autologous cells. Expansion of these
cells can be tenuous, with the mature adult cell’s propensity towards quiescence.
Isolation and expansion can also result in uncontrollable and variable phenotype
changes in the endothelial cells.[61]
As past studies have reported inosculation of prevascular implants at 2-5 days[84],
vascularization dynamics in literature have not focused on early time points preceding a
few days following implantation. Our study reveals that an earlier observation window
informs us on the relative rapidity of endothelialization around cellular constructs and
reveals that the crucial advantages to a prevascular network might be best seen within
six to 12 hours of implantation. By this period, the groundwork for a vascular pedicle
feeding the implants has already been laid, with evidence of reorganization towards a
more mature host-implant vascular network. Vascular tissue engineering strategies that
proceed from this point should promote lumen formation and patency of the existing
vascular architecture.

2.3 Chapter Specific Methods
2.3.1 In vitro SPEC and Fibroblast-spheroid Development
Human adipose Microvascular Endothelial Cells (HAMEC) (ScienceCell, Carlsbad, CA,
7200) and Normal human dermal fibroblasts-Adult (NHDF-Ad) (Lonza, CC-2511) were
used to form 1:4 cell mixtures to create SPECs and Fibroblast-only spheroids. Cell
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culture notes are document in Chapter 5. The scaffold-free prevascular endothelial
fibroblast constructs (SPECs) were modifications of a protocol established by Czajka
and Drake[64] . Rod-shaped troughs of 0.9 cm by 0.1 by 0.5 cm depth were constructed
in 2% UltraPureTM Agarose (Invitrogen, Carlsbad, CA, 16500-100) and high density 4:1
mixtures of 720,000 NHDF-Ad cell and 180,000 HAMECs were pipetted into the troughs.
Cells were then cultured in a 2:1 mixture of FGM2 and EGM2 for 3 days. Implants were
either collected in Dulbecco’s Phosphate Buffered Saline for use in surgical implantation
or collected and fixed in 4% Paraformaldehyde for histology. Fibroblast-only spheroids
(FOS) were constructed similarly with 900,000 NHDF-Ad and no HAMECs. Silicone
fragments of rectangular box dimensions of 0.6 cm by 0.1 cm by 0.1 cm (to match the
eventual dimensions of the cell-based rods) were autoclaved and stored in DPBS in
preparation for implantation.

2.3.2 Rat Submuscular Pocket Surgery and TEC Implantation
Animal procedures were conducted following approval by the Institutional Care
and Animal Use Committee (IACUC) of the Medical University of South Carolina. Fiftyfour Sprague Dawley rats (Charles River Labs, Wilmington, MA) were divided into 3
groups: SPECs (n=15), FOS (n=15 rats), and silicone implants (n=15 rats). Nine rats
were set aside for sham surgeries. Surgeries were performed as described by Calder et
al.[47] Implants were placed in submuscular pocket, with the long axis oriented parallel to
the hind limb running proximal to distal. Five rats within each implant group were
sacrificed at 6hr, 12 hr., and 24 hours, with muscle excised from the left hind limb en
bloc with implant or sham surgery, placed in O.C.T Compound (Tissue-Tek 4853,
Torrance, CA), and frozen at -70 °C for cryosectioning. Muscle from the right limb was
harvested for comparison.
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2.3.3 Immunofluorescent Imaging, Immunohistochemistry, and Western Blots
General immunofluorescence, immunohistochemical staining, and Western Blot
protocols are documented in Chapter 5. Tissue sections were fixed in 4%
paraformaldehyde solution for 30 min and subjected to hematoxylin and eosin staining,
direct or indirect immunofluorescence labeling. Tissue sections were directly labeled with
Hoechst 33342 nuclear stain (Molecular Probes, 1:10000), and Alexa FluorTM phalloidin
488 (ThermoFisher Scientific A12379, 1:500) for f-actin. Selected sections were stained
with primary antibodies to von Willebrand Factor (Abcam, Catalog# ab6994, 1:1000),
CD31 (Abcam ab28364, 1:50), human CD31 (monoclonal antibody) (R&D Systems
BBA7, 1:25), smooth muscle actin (ThermoFisher Scientific PA5-19465, 1:1000).
Primary antibodies were fluorescently tagged with the secondary antibodies Alexa
FluorTM goat anti-mouse 488, goat anti-rabbit 546, goat anti-mouse 546, and goat antirabbit 633 (ThermoFisher Scientific, A-11001,11035,11030,21070, 1:500). Sections
were mounted on Colormark Plus microscope slides in Prolong Gold antifade reagent
(Molecular probes P36934). SPECs and FOS were collected after 1, 2, and 3 days of
culture in 2% linear agarose molds as previously described. Samples were snap frozen,
and mechanically homogenized in RIPA lysis buffer with protease inhibitor cocktail.
Samples were maintained in constant agitation for 2h at 4°C, centrifugated for 20 min at
16,000 g at 4°C. Supernatant was stored in fresh tube at -20°C. PierceTM BCA Protein
Assay kit (Thermofisher Scientific 23227) was used to estimate protein concentration for
samples as per manufacturer’s instructions. Prior to gel electrophoresis, samples were
diluted in RIPA buffer to attain 20 ug of protein in 20 uL solution, and further diluted 1:1
in 2x Laemmli Sample buffer to attain 40 uL loading volumes. Samples were loaded onto
Any kDTM Mini-Protean® TGXTM Precast Protein Gels. Following protein separation and
overnight transfer onto PVDF membranes, western blots were performed using
antibodies towards GAPDH (loading control) (CalBioChem CB1001, 1:1000), VEGFR2
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(Abcam ab39256, 1:900), VE-Cadherin (ThermoFisher Scientific 36-1900, 1:250), vWF
(Abcam, ab6994, 1:500), and DLL4 (Abcam ab7280, 1:1000).

2.3.4 Confocal Microscopy
Confocal images were acquired using Leica TCS SP5 AOBS Confocal
Microscope system (Leica Microsystems Inc., Buffalo Grove, IL) and collected as
average projected z-stacks at 20x and 40x magnifications. Stitching was performed
using LAS AF v2.6.3 Build 8173 and encompassed the entire visible cross section of
each implant. Images were auto-enhanced and analyzed using ImageJ (NIH, Bethesda,
MD). To analyze endothelial cord organization, stitched 40x (512x512) confocal images
of sections stained with antibodies for vWF and CD31 were segmented as follows.
Average projected images (10um depth) were autothresholded in ImageJ (Otsu auto
threshold[85]), and binarized. Perimeter of the implants and endothelial capsule around
implants were drawn freehand. Binary images were used to calculate microvessel area
fractions of the implant. Binary images were skeletonized using an ImageJ plugin,
provided by Arganda‐Carreras et al[86], with branches pruned by lowest intensity voxel.
Resulting images was used to calculate number of junctions and vessel branch lengths.

2.3.5 Statistical Methodology
Statistical Analysis was performed using IBM SPSS for Windows Version 24.0
(Released 2017, Chicago, SPSS Inc). Levene’s test for homogeneity of variance was
used to determine equality of variances (α=0.05). For data with equal variance between
groups, One-way ANOVA was performed with post hoc application of Bonferroni’s t test
used to compare microvessel density, degree of penetrance of vessels, and branching
density among the three implant types at each time point. For data with unequal
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variances, Welch’s one-way ANOVA was performed with Dunnett T3 post-hoc
corrections.
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3 STRATEGIES TO IMPROVE SPEC
VASCULARZIZATION
While past scaffold-free implants have successfully inosculated with the host vasculature
within hours, successful anastomosis connotes an intact route of blood flow. Blood
perfusion of implants within 24h post-implantation is an unmet need in tissue
engineering. While lumen-like structures are visible in SPECs as early as 12h postimplantation, lipophilic dye perfusion arrests on impact with the implant/muscle interface,
revealing a lack of a continuous hollow conduit through the invading endothelial cords
and existing microvessel architecture of implants. We hypothesize that lumen formation
is the rate limiting step in implant anastomosis at time points past 12-24h and investigate
methods for inducing lumen formation and tubulogenesis in the SPEC prior to
implantation. Early in vitro lumen formation should improve in vivo implant engraftment
and, ultimately, implant survival. Summarized in the proceeding sections are efforts
undertaken to improve lumen formation in SPEC endothelial cords through exogenous
overdose of proangiogenic factors, inducing endothelial realignment through media
perfusion, and incorporating perivascular cells in in vitro conditions.

3.1 Dosing SPECS with Vascular Endothelial Growth Factor
3.1.1 Rationale for Pre-Dosing SPECs with Proangiogenic factors
One deceptively simple approach to inducing lumen formation is pre-treatment of
implants with Vascular Endothelial Growth Factor-A (VEGF-A). In response to
proangiogenic factor stimuli, endothelial cells undergo rearrangement of cell-cell
junctions, shape changes, chemotaxis, and increased proliferation.[87] The
proangiogenic effects of VEGF-A are primarily mediated by its interaction with VEGF
Receptor-2 (VEGFR2).[88] VEGF/VEGFR2 signaling regulates endothelial cell-cell
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junctions, endothelial cell barrier function in vessels, migration, and proliferation.[87-89] If
and how VEGF/VEGFR2 signaling pathways contribute specifically to lumen formation is
an area of active research.
There is preliminary evidence that VEGF may play a large role in macrostructural
changes in vascular spheroid self-assembly. Gentile et al. demonstrated that exogenous
VEGF treatment of embryonic mouse allantoic tissue, a prevascular tissue composed of
a mixture of endothelial and hematopoietic progenitors,[90] results in fusion of existing
microvessels into single, large-caliber, central canals.[91] These uniluminal spheroids
could actually fuse into longer structures[92, 93], a finding that is particularly important to
3D tissue bioprinting. Fusion of cords in segments of allantois is consistent with the
differential adhesion hypothesis (DAH), whereby cells rearrange themselves to minimize
interfacial energy.[32] Consequences of DAH theory in microvessel formation is further
explored in Chapter 4. The allantois tissue model involves the formation of a primitive
vascular plexus, a model we have partially recapitulated using adult stromal-derived
cells.[94, 95] . Several in vivo studies have demonstrated that both soluble and bound
VEGF has a role in variable blood vessel diameters. Extracellular matrix bound VEGF
isoforms play a larger role in formation of gradients that drive endothelial cell chemotaxis
and migration.[96] Modeling VEGF-induced endothelial tissue patterning requires an
understanding of VEGF-ECM interaction as well as temporal mapping of endothelial
movement and clustering. The SPEC, therefore, can serve as an ideal model to probe
the effect of VEGF treatment on vessel self-assembly. It contains an ECM-producing
cellular component (normal human dermal fibroblasts) and microvascular endothelial
cells that spontaneously form cords in vitro, but do not usually arrange themselves to
form hollow tubular structures.
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3.1.2 Exogenous rhVEGF165 dosing of SPECS Results in a Dose and Timing
Specific Changes in Lumen Formation During Self-Assembly
SPECs were grown in linear agarose molds. They were dosed after at least 1-day of
incubation, which allowed cells to form preliminary contacts and fibroblasts to begin
stabilizing the constructs with extracellular matrix deposition. A cohort of implants (n=3
per treatment) were treated with 50 ng/mL recombinant human VEGF165, 10 ng/mL, 0.3
ng/mL, or media starved of VEGF. Implants demonstrated a dose-specific increase in
presence of large-caliber cavities encircled by an endothelial lumen (Figure 3.1) as well
average lumen diameter (Figure 3.2). At 50 ng/mL, large central cavities (>100 um)
were visible, while many smaller-caliber (20-40 um) lumen-like structures were visible in
implants treated with 10 ng/mL VEGF. At lower levels of VEGF, only one or two isolated
small caliber cavities could be seen throughout the implants. F-actin cytoskeletal
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structures in the construct stroma also encircled lumen-like cavities, suggesting a
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FIGURE 3.1: SPECs formed hollow tubular cavities with a dose dependent increase in luminal diameters.
Implants stained with phalloidin (green) and anti-CD31 (red). (a-c) VEGF Starved implants did not present
with hollow lumens (d-f) Normal media treated implants rarely developed cavities (g-i) 10 ng/mL treated
SPECs formed a large number of small diameter cavities encircled by endothelial cells and condensed factin filaments (j-l) 50 ng/mL treated implants presented with large caliber lumens with some spanning the
width of an implant
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rearrangement demonstrates reorganization of extracellular matrix and fibroblasts
around forming cavities. Lumen formation in the SPECs was also dependent on time of
treatment, with implants dosed with 50 ng/mL from day 1-3, day 2-4, and day 3-5 (n-3
per group) (Figure 3.2). The longer the amount of time a SPEC pre-assembled in vitro,
the smaller and sparser the number of endothelial-lined cavities. This may provide
evidence of two possible phenomena: increased matrix deposition serves as a barrier for
diffusion of VEGF or increased SPEC cord formation resists reorganization induced by
exogenous treatment. Both these scenarios are modeled in Chapter 4. Cavitation
appears to be pre-empted by F-actin organization in implants treated at later time points,
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where lumen-like patterns were seen in phalloidin stains, but without true cavity
formation (Figure 3.4).
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FIGURE 3.3: The number and the average diameter of lumen-like cavities in the SPECs treated with 50
ng/mL rhVEGF-165 was shown to be dependent on time of treatment (CD31 in red; phalloidin in green).
(a-c) Constructs treated at 24-72h of incubation developed large caliber central lumen (d-f) Constructs
treated at later time points (96h-120h) developed small caliber vessels similar in size and number to
implants dosed with 10 ng/mL rhVEGF-165
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100 um
FIGURE 3.4: Cavitation pre-empted by F-actin reorganization in low dose (10ng/mL) exogenous
VEGF, at later treatments on D3-D6 (CD31+ endothelial cells in red, phalloidin f-actin stain in blue).
ECM reorganization constitutes an “energy cost” to vessel formation. Without ECM, however,
capillaries are unstable. Optimization of vessel formation: (Cost of ECM reorganization) – (ECM
stabilizing effect on vessel structures)

3.2 Growth of SPECs in Perfusion Chambers
3.2.1 Rationale for Growth of SPECs in Perfusion Chamber
One of the major limitations previously cited in SPEC assembly is that cells are grown in
static conditions.[95] Vascular development in adults typically occurs in the vicinity of an
area already perfused by neighboring vasculature. Microvessel patency, thus, might
require continuous flow. We see evidence of lumen formation 12h post-implantation in
SPECs, but segments of the vessel may have collapsed due to lack of pressurization by
blood flow and the ubiquitous presence of mechanical stress from animal movement and
extracellular matrix turnover. We do not see red blood cell perfusion in implanted SPECs
consistently until past 72h post-implantation. We hypothesize that prevascularization in a
perfusion chamber where endothelial cells and fibroblasts are exposed to unidirectional
flow may stabilize forming endothelial lumen.
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Shear stress induced by perfusion has a well-documented role in changing the
phenotype of endothelial cells. In vivo, pulsatile directed flow has been shown to induce
endothelial cell expression of genes associated with cell cytoskeletal orientation.[97] In
vitro, shear stress alone has been shown to alter cytoskeletal arrangements and cell
shape, as well as alter gene expression.[98] For instance, endothelial cells respond to
shear stress through increased expression of flow-responsive transcription factors such
as KLF2 and KLF4, members of the Kruppel-like factor family. KLF2, and to some extent
KLF4, has been implicated in improving angiogenesis, increasing vascular tone, and
reducing inflammation and clotting that may result in atherosclerotic occlusion of
vessels. In fact, this response may be modulated by releasing ATP which may interact
with purinergic signaling receptor P2X4 on endothelial cells.[99] ATP release is also
intimately correlated with sterile inflammation associated with surgical trauma during
implantation of tissue engineered constructs, suggesting a potential biological rationale
for rapid vascularization in the context of surgical stress.[100]

3.2.2 Growth and Fusion of SPECs in Perfusion Chamber
Our eventual model for scaffold-free prevascular construct assembly under
perfusion was inspired by a modular vascular construct model created by Sefton and
Khan.[101] In said model, collagen tubes seeded with endothelial cells were packed into a
chamber of a microfluidic device. The interconnected void spaces formed by random
packing of these tubes permitted flow at 0.5 mL/min (resulting shear of 0.64 dyn/cm 2).
Endothelial cells reorganized around the flow patterns to create channels resembling a
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capillary bed formation. We created a scaled-down version of this set up, replacing
endothelial seeded capillary tubes with rod-shaped SPECs (formed as previously
discussed in 2% agarose molds). These rods were packed into a chamber within 3%
agarose, with polyethylene tubing forming an inlet and outlet as shown in (Figure 3.5).

Outlet
rate=variable;
drops about 50
ul/min a day
with increased
resistance

Inlet flow
rate=8001200 ul/min

Flow
direction

100 um

FIGURE 3.5: (top) A cohort of SPECs were harvested as three segments that were arranged
concentrically within a perfusion chamber constructed within an agarose mold. Oxygenated media
was delivered to the inlet by a peristaltic pump. Outlet flow was recirculated back to the media
reservoir. (bottom). Endothelial tubes aligned to channels between rods in perfusion chamber.
Perfusion rate ranged from 800 ul/hr to 1.2 mL/hr. The three rods fused over 3 days.

Flow into the chamber was directed from a T-75 flask containing EGM2 media that could
freely mix with incubator gas mixtures, while flow out of the chamber was collected in a
separate flask, with serial measurements taken to note flow changes through the
chamber during the incubation period. A FisherbrandTM mini-pump variable flow device
was used to direct flow into the chamber at a rate of 800-1200 ul/min.
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The experiment was repeated with 3 SPECs a total of 4 times (a total of 12 SPECs were
created and fused). Each attempt resulted in successful fusion of SPECs; however, the
characteristics of the formed conduits for flow differed significantly during each attempt.
Most of the fused-SPECs showed evidence of tearing due to mechanical stress;
however, in at least two of the fused SPECs, however, a few channels were observed
with endothelial cells aligned at the margins in the direction of the flow path (Figure 3.5).
This suggests that if mechanical tearing was avoided, endothelial cell organization in
between SPECs could occur in response to perfusion.

3.3 Incorporation of Pericytes into SPECs
3.3.1 4.3.1 Rationale for incorporation of Pericytes
Perivascular cells play a role in stabilization of vascular structures during angiogenesis
and maintaining vascular homeostasis.[67] There are two cell cohorts that fall under this
label: vascular smooth muscle cells and pericytes. As our previous prevascular implant
involved cords resembling capillary networks, we will concern ourselves with pericytes,
the cells that are in direct contact with a stable, mature capillary endothelium. Smooth
muscle cells surround larger caliber vessels and are separated from the endothelial cell
layer by a basement membrane and elastic lamina.[67] Pericytes are difficult to
demarcate by specific markers as their expression patterns are specific to their tissue of
origin, activation state, and culture conditions. Additionally, pericytes resemble
mesenchymal stem cells, and may serve as a potential tissue-resident source of MSCs.
Pericyte-specific markers include Neural/glial antigen 2 (NG2), Platelet-derived growth
factor receptor beta (PDGFRβ), and alpha-Smooth muscle actin (α-SMA). We
demarcate our perivascular cohort with α-SMA, as we do not anticipate confusion
between pericytes and their macro-vessel analogs, smooth muscle cells.
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In endothelial-pericyte coculture models, Olridge and D’Amore have
demonstrated comparable levels of endothelial cell proliferation inhibition by pericytes at
1:1, 2:1, 5:1, and 10:1 ratios. 20:1 ratios and higher ratios, however, resulted in
unimpeded EC growth rates within 3 days of coculture.[102] Studies extending to 3dimensional cocultures in Matrigel assays, have observed pericyte influence on nascent
endothelial tube formation. Endothelial-pericyte ratios of 10:1 and 20:1 showed
observable reduction in endothelial cord areas as opposed to higher ratios (40:1,
80:1).[103] Repression is thought to be associated with CXCR3-induced vessel
dissociation through the interaction of pericytes and endothelial cells. This conclusion
trends with the notion that pericytes have a functional role in inhibiting immature vessel
growth.[103] On the other hand, pericytes recruitment to endothelial-cell lined tubes is
associated with basement membrane matrix deposition that might be necessary for
creating a distinction between basal versus apical surface of endothelial cells.[104, 105]
This is demonstrated by upregulation of integrins (α5β1, α3β1, α6β1, and α1β1), a finding
specific to EC-pericyte interactions, not endothelial cell monocultures. Dysregulation of
integrin signaling in this context results in larger lumen diameters, which, paradoxically,
is associated with poor vessel stability.[105] Given that poor vessel patency has been
cited in our past papers as one of the major limiting factors to the use of prevascular
endothelial-fibroblast constructs, we expect the added stability conferred by endothelialpericyte interactions might induce early maturation and stabilization of capillary-like
structure in vitro and improve vessel patency when these constructs are implanted. This
would be reflected by smaller caliber lumen sizes in vivo; however, we do not yet know
the effect on endothelial tube formation in 3D fibroblast-endothelial self-assembled
constructs.
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Existing pericyte-endothelial coculture models already demonstrate signaling
specific to pericyte-endothelial interactions. Pericyte recruitment to capillary tubes is
expected to induce stabilization through increased production of TIMP-2 by endothelial
cells and TIMP-3 by pericytes, as demonstrated in 3D collagen matrices.[106] Capillary
tube regression in such a case progresses through MMP-1, MMP-10, and ADAM-15
dependent manner. Lumen formation is also controlled by TIMP-2 and 3 target, MT1
MMP (membrane type 1 MMP).[106] Authors also note alpha2beta1 (not mentioned early)
observed in EC-pericyte cocultures. CDc42, MT1-MMP, and alph2beta1 integrin are in
the signaling cascade involved in lumen formation.[105, 107]
There are several examples of vascular grafts and cocultures incorporating
pericytes. Weinberg and Bell devised a trilayer blood vessel model composed of an
endothelial intima, a media composed of collagen and smooth muscle cells, and an
adventitia composed of adventitial fibroblasts and collagen.[108] Although the model
needed to be supported by an external Dacron mesh, it served as an example of forming
an arterial structure that acknowledged the biological importance of perivascular cells
such as vascular smooth muscle cells. He et al. uniformly seeded a Poly(ester-urethane)
urea scaffold with human skeletal pericyes in a rotational vacuum seeding device and
implanted resulting tissue engineered vascular graft in rats. Implanted grafts developed
a bilayered structure with a distinct host-derived endothelial intima and a media
generated by the graft cells.[109]
To date, studies of pericyte behavior in tissue engineering seems limited to
scaffold based technologies. There is some consensus that pericyte differentiation and
growth factor release is modulated by the cell’s interaction with scaffold biomaterials.
We, however, hope to examine pericyte behavior in a self-assembly, scaffold-free
setting. Notably past publications have demonstrated that a primitive vascular network
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can form within a precise ratio of endothelial cells and fibroblasts.[64] A primitive network
refers to the capillary-like network that contributes to the embryonic circulatory system
composed of angioblast clumps.[110] The resulting stroma can be strengthened with
exogenous administration of matrix-promoting growth factors (e.g. TGFbeta1) without
disrupting the endothelial cord arrangement.[64] Pericyte-EC interactions are expected to
stabilize existing vessels and inhibit tube formation in vitro; however, their effects on the
initial capillary cord network forming during self-assembly in a scaffold-free setting has
not been observed. Scaffold-free endothelial-fibroblast assembly has been suggested as
a method of prevascularizing tissue constructs without the use of scaffoldingbiomaterials that may initiate a foreign body response. However, as suggested by
Czaijka et al., patterning of vessels within a matrix entirely supplied by fibroblasts is
highly dependent on a designated cellular ratio. We anticipate that introduction of a third,
invasive cell type with a well-documented interaction with endothelial cells, will perturb
the primary vascular network formation in a ratio dependent manner as well.
4.3.1 Incorporation of Pericytes into Scaffold-Free Prevascular Constructs
Using Celltracker DeepRed-labeled human adipose microvascular pericytes
(HAMVPCs)(Angio-Proteome, cAP-0043), we generated tri-culture spheroids with an
8:2:1, 40:10:1, and 80:20:1 ratio of NHDFs (normal human dermal fibroblasts), HAMECs
(human adipose microvascular endothelial cells), and HAMVPCs (n=3 for each type).
Additionally, we grew 3 extra SPECs (4:1 ratio of fibroblasts to endothelial cells) that
were plated on a 90% confluent plate of HAMVPCs, to assay for pericyte invasion of
implants. Implants were grown in a 2% agarose mold over 3 days. Implants were
collected and cryosectioned to assess pericyte incorporation, association with
endothelial tubes, and invasion of plated SPECs. Figures 3.6 and 3.7 shows endothelial
cord arrangements (red) and pericyte distribution (blue), as well as smooth-muscle actin
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expression. The pericytes did not appear to distribute to encircle forming endothelial
cords corresponding to the assumed function of perivascular cells. At 80:20:1 and
Normal Spec

8:4:1 SPEC

a

b

40:10:1 SPEC

80:20:1 SPEC

d

c

CellTracker

e
CD31

i

f

g

h
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k
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FIGURE 3.6: (a-d) Pericytes were incorporated into SPECS at various ratios (Fibroblast :
Endothelial: Pericyte). Few morphological changes were apparent in Hematoxylin and Eosin
stains. (e-h) CellTracker DeepRed labeled pericytes spread uniformly throughout the implant,
without any directly observed interaction with endothelial cords. (i-l) Microvessel density (CD31
endothelial cells in red) appears enhanced by incorporation of pericytes; however, at higher
pericyte densities (j) microvessel architecture appears disrupted.

40:10:1 ratios, pericyte inclusion appears to have a paracrine effect on microvessel area
fraction, with increasing density of pericytes corresponding to an increase in endothelial
cord density. However, at the highest density of pericytes (8:2:1 implants), spheroids
presented with disrupted vascular patterns, with a corresponding decrease in
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microvessel area fraction. This appears to corroborate reports of endothelial cord
disruption mediated by interaction of pericytes with the endothelial CXCR3 receptor.[103]
HAMPVCs do not appear to induce lumen formation in endothelial cords in static culture.
Additionally, α-smooth muscle actin expression is low in the static tricultures (Figure
3.7), despite validation of pericyte cell incorporation through CellTracker staining. This
8:2:1
SMA

SPEC
SMA

100μm
CellTracker

40:10:1
SMA

100μm
CellTracker

100μm

80:20:1
SMA

100μm

100μm
CellTracker

100μm

100μm

FIGURE 3.7: (a) Smooth muscle actin-α expression is minimal in SPECs without pericytes. (b-d) SMA
expression increases with presence of pericytes; however, only a small fraction (>20%) of cellTracker
labeled pericytes (e-g) colocalize with SMA+ regions within the implants suggesting low basal
expressivity of SMA in Human adipose microvascular pericyte primary cells

may suggest poor phenotype stability of pericytes from Angio-proteomieTM. Only the
plated SPECs with pericyte invasion demonstrated any increase in smooth muscle actin
expression. Lumen-like structures are apparent in these invaded SPECs, although they
are not encircled by endothelial cells (Figure 3.8). This coupled with the lack of much
pericyte infiltration (a maximum of 3 pericytes were visible in the cross sections) may
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suggest a mechanical stress mediated structural change in the implants and induction of
smooth muscle expression in stromal cells (fibroblasts).

100μm
SMA

VEGFR2

FIGURE 3.8: (Top) Hematoxylin and Eosin stain of SPECs plated on monolayer of pericytes
show sinusoid like channels throughout the implant cross section. (bottom) Pericytes (SMA+
cells) invaded into the SPEC, but did not alter the endothelial cord pattern observed in implant
(VEGFR2+ cells).

Further experimentation with HAMPVCs was discontinued primarily due to low αsmooth muscle actin expression in the cells from Angio-ProteomieTM. As indicated
earlier, α-smooth muscle actin is used to distinguish relatively contractile, perivascular
cells (including pericytes and smooth muscle cells) from fibroblasts. HAMPVCs either
have poor phenotype stability in 3D culture or were poorly typed by the manufacturer.
There is some controversy concerning the distinction of pericytes and tissue-resident
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mesenchymal stem cells, with some sources arguing that the distinction between these
cell types is lost in in vitro conditions,[111] which may account for phenotype instability.

3.4 Chapter Specific Methods
Human adipose microvascular pericytes (HAMPVCs) (Angio-Proteomie, cAP-0043) were
plated on culture treated T-25 plates. These plates were coated with 2 mL quick coating
solution for 30 minutes (Angio-Proteomie, cAP-001) to allow adhesion of pericytes.
Solution was aspirated prior to seeding. HAMPVCs received Pericyte Growth Medium
(Angio-Proteomie, cAP-009), with media replaced every 2-3 days. Cells were split at
90% confluence. HAMEC and NHDF cells were cultured as mentioned in Chapter 5.
Pericytes were labeled with CellTracker DeepRed (ThermoFisher Scientific, C34565)
following manufacturer’s instructions. Fibroblast, endothelial, pericyte triculture spheroids
were constructed in a 9mm x 1mm x5 mm (height) linear agarose mold at the following
ratios:
•

□

3 x 8:2:1 construct involving: 654544 fibroblasts ,163636 endothelial cells,

81818 pericytes per construct
•

□

3 x 40:10:1 construct involving: 705880 Fibroblasts,176470 endothelial

cells,17647 pericytes per construct
•

□

3 x 80:20:1 construct involves: 712880 Fibroblasts, 178220 endothelial

cells,8911 pericytes per construct
•

□

3x SPECs involving: 720,000 Fibroblasts and 180,000 endothelial cells.

Constructs were collected after 3 days of incubation, with half of each implant harvested
for whole mount fluorescent microscopy and half embedded in O.C.T cryopreservant on
ice for sectioning. Implants were stained with CD31 (Abcam ab28364, 1:50) and αsmooth muscle actin (ThermoFisher Scientific PA5-19465, 1:1000).
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4 MODELING VEGF-INDUCED LUMEN FORMATION IN
SCAFFOLD FREE IMPLANTS AND FUTURE
DIRECTIONS
4.1 Spheroid Condensation and Endothelial Clustering associated with
VEGF Treatment
Perhaps the most surprising finding within our in vitro studies modifying the scaffold free
prevascular construct design is that an increase in exogenous VEGF alone can
consistently cause a hollow lumen formation in a 2-adult cell type system. Gentile et al,
as discussed in Chapter 3, have demonstrated a similar reorganization in allantois
derived spheroids[91]; however, allantois tissue has the advantage of containing a
number of pluripotent vascular precursors, with VEGF induction potentially resulting in
differentiation into cell types supporting lumen formation (e.g. perivascular cells). The
SPEC model differs by containing relatively terminally differentiated, mature cells. This
comparatively simple set up provides an opportunity to computationally model lumen
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formation and determine if existing theories for cell aggregation and sorting, such as the
differential adhesion hypothesis, can explain dose and time dependent changes in our
SPECs in response to VEGF. Specifically, we hypothesize that VEGF improves the
ability for endothelial cells to cluster, or, rather, reduces the energy cost of endothelial
∆x=7.0%
∆x=30.1%

1 mm

t=24h

1 mm

1 mm

t=36h

∆Volume=
18.9%

∆Volume=
29.9%

~0
ng/ml

10
ng/ml

∆x=42.7%

t=48h

∆Volume=
33.2%
50
ng/ml

1 mm

t=60h

∆Volume=
36.4%
100
ng/ml

FIGURE 4.1: (Top) SPECs with Endothelial cells labeled with cellTracker were imaged during
self-assembly using Lionheart Fx. Constructs treated with 50 ng/mL at 48 h exhibited tissue
condensation, with an accordion-like folding pattern. (Bottom) Endothelial-only spheroids
showed similar condensation behavior, with increasing doses of VEGF resulting in increased
condensation of endothelial structures and central hollowing at 100 ng/mL doses. The red circle
indicates the initial cell spread at 1h following seeding, and volumes were examined at 12h.

cells to form interfaces with each other. This hypothesis is supported by live-cell imaging
using the Lionheart Fx® scope. We examine spheroid assembly in real-time and examine
the effects of VEGF dosing on the kinetics of cell reorganization. SPECs typically
condense in the first 48 hours after endothelial cells and fibroblasts are seeded in
agarose molds, an almost crystalline process were cells reorient and reach an
arrangement that seems energetically favorable. During this process, the cytoskeletal
filaments in fibroblasts and the stromal extracellular matrix reorganize along the long
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axis of the SPEC.[94] With VEGF treatment, SPECs condense at a much faster rate and
to a greater extent (Figure 4.1). This process appears to outstrip the dynamics of
cytoskeleton rearrangement, evidenced by an accordion-like folding of the rod-shaped
implants. As fibroblast (NHDF) spheroids did not respond significantly to treatment with
t=30
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0 ng/mL

0 ng/mL

0 ng/mL
t=3 h

t=30
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10 ng/mL
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50 ng/mL

50 ng/mL
t=30
min

100 ng/mL

t=6 h

10 ng/mL

t=30
min

50 ng/mL

t=6 h

t=3 h

t=6 h

100 ng/mL

100 ng/mL

FIGURE 4.2: Fibroblasts and endothelial cells (1:4) ratio were plated on agarose wells and allowed
to attach to directly to the adherent exposed plate on the bottom of the well. The HAMECs labeled
with Mitotracker DeepRed (red) showed a VEGF dose-dependent response in organization,
remaining marginal at low doses (0-10 ng/mL) and clustering at the center for higher doses (50-10
ng/mL). Mitotracker staining increased with time at higher doses.
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VEGF, we decided to examine endothelial cell behavior in isolation. A high-density
endothelial cell suspension grown in non-adherent wells and dosed with VEGF showed
increased tendency to cluster. In fact, at higher doses (50--100 ng/mL), endothelial cells
formed dense spheroid-like aggregates that did not readily disassemble when physically
probed, potentially indicating a loss of contact-inhibition.
Two-dimensional behavior of cells in the SPEC was approximated by plating a
1:4 mixture of cells into an agarose well with the bottom of the well punched out to allow
cells to attach to the plate. While the substrate modulus resulting from cell-plate
adhesions changes the material properties of the cell mixture, it simplifies tracking of cell
sorting behavior with live-cell microscopy. HAMECs were pre-labeled with MitoTracker
DeepRed FM (ThermoFisher M22426) which primarily labels depolarized (activated)
mitochondria within the cells. Cell labeling increases/decreases with
increased/decreased mitochondrial depolarization, a marker of increased oxidative
phosphorylation. This labeling serves as a simplified marker of endothelial activity,
although we note that certain cellular processes, such as proliferation, are primarily
glycolytic and increased activation of these processes would not be represented by
increased MitoTracker staining. (Figure 4.2) shows a 6h time series of cell sorting
(50,000 cells loaded initially, per 300 um diameter x 300 um depth well) with and without
VEGF dosing. Cells treated with low levels (0-10 ng/mL) showed a peripheral distribution
of endothelial cells, while at higher doses (50-100 ng/mL) endothelial cells were found at
the interior of the cell plates with a greater tendency to aggregate. MitoTracker staining
increased within hours of incubation in the wells, suggesting increased mitochondrial
depolarization during VEGF treatment.
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Endothelial cell activation in SPEC spheroids is more explicitly assayed by
probing for activation of Jak/Stat3 signaling pathway downstream of VEGF/VEGFR2
binding (Figure 4.3). Phosphorylated Stat3 (at tyrosine residue 705) is a biomarker of
VEGF activation of endothelial cells and is often constitutively active in the vascular
endothelium of tumors, playing a functional role in endothelial cell survival and
transformation.[112] In 100 ng/mL VEGF-treated SPECs, pStat3 was elevated compared

FIGURE 4.3: ELISA was conducted
on cell lysates collected from SPECs
treated for ~0,1, and 100 ng/mL
VEGF after 1 h of treatment. pStat3
was significantly elevated in SPECs
dosed at 100 ng/mL when compared
to 0 and 1 ng/mL doses (p>0.01, n=3
per group).

untreated controls. At lower doses (1 ng/mL and 10 ng/mL), however, the differences
from controls were not significant. Thus, while the elevated pStat3 does provide a
biological rationale for calling endothelial cells in VEGF treated SPECs activated, the
clustering phenomenon observed in the live cell assays are unlikely to be due to this
specific pathway; the clustering phenomenon increases within a dynamic range
encompassing 1 ng/mL and 10 ng/mL VEGF treatments. In future studies, we anticipate
exploring the specific pathways downstream of VEGF/VEGFR2 signaling that are
associated with a loss of contact inhibition and increased homotypic cell adhesion. For
cell-cell interface modeling purposes, however, we primarily need to establish a VEGFdose dependence on cell clustering behavior and we need to determine if this response
is specific to endothelial cells within the spheroids.
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4.2 Role of Fibroblast behavior in VEGF-treated implants
This latter point can only be confirmed by assaying fibroblast behavior in isolation under
VEGF treatment. As previously discussed, fibroblast-only spheroids did not appear to
condense in response to VEGF treatment. While fibroblasts produce low levels of VEGF,
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FIGURE 4.4: (Top) Collagen Type I deposition (red) by fibroblasts (Hoechst-stained nuclei in blue)
was unaltered by VEGF treatment from 0-100 ng/mL. Proliferation as measured by cell count and the
number of mitotic events did not vary significantly between treatment groups and time points
(alpha=0.05) (Repeated Measure-ANOVA using SPSS)

there is little evidence in literature that VEGF induces an autocrine response in these
cells under normal conditions. Gutpell and Hoffman, however, reported that high (50
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ng/mL) of murine VEGF164 induced increased fibrotic response in dystrophic fibroblasts
derived from Duchennes muscle Dystrophy murine muscle.[113] By treating low density
plated (2,000 cells per cm2) fibroblasts with rhVEGF165, we explored changes in
fibroblast proliferation, number of mitotic events, collagen type I deposition, and
migratory propensity (random-movement assay), summarized in Figure 4.4. VEGF
induction did not appear to alter proliferation, collagen deposition, or induce changes in
motility of fibroblasts at doses ranging from 0-100 ng/mL. Therefore, we exclude
fibroblast behavioral changes from our initial computational model of VEGF-treated
SPEC self-assembly. Modulating fibroblast behavior in our spheroid, thus, could be a
method to improve lumen formation in a manner that VEGF treatment alone cannot
accomplish.

4.3 Mechanism of Lumen formation and Role of VEGF
Condensation of endothelial structures in SPECs due to either decreased contact
inhibition or increased adhesions may bring forming endothelial cords and lumens in
closer proximity to each other. This allows fusion of smaller lumens that may form
spontaneously or with basal VEGF input into larger caliber structures. However, this still
leaves the question of how small caliber lumen formation occurs in our spheroid models,
and we look to literature as well as our in vitro findings to provide several key theories.
Endothelial tubulogenesis and lumen formation has not been as well studied as
epithelial tubulogenesis. This is due to the difficulty of producing visualizable blood
vessel tubulogenesis models, and the relative dearth of reliable apical/basal markers.
Additionally, epithelial tubulogensis studies benefitted from earlier Drosophila genetic
screens.[114] Epithelial tubulogenesis can proceed through a number of plausible
methods: cell sheets wrapping in a tube shape; multicellular cavitation, where cells are
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eliminated from the center of a spheroid; cord hollowing, where epithelial cords change
shape and unzip to reorient around a hollow tube; cell hollowing, were unicellular tubules
form through a process of vesicle elimination of cytoplasm.[114] Of these, intercellular and
intracellular cord hollowing (spontaneously and during angiogenic sprouting) are most
commonly associated with endothelial cell tubulogenesis.[115]
Both intra- and intercellular cord hollowing requires reorganization of cell
components into basal (directed outside of the forming vessel) and luminal/apical
(directed into the cavity of a vessel) surfaces; hence, we merge these potential
mechanisms together as a “Polarization Model” of vascular lumen formation. At a cellular
level, apicobasal polarization involves vacuolization of cells, with accumulation of
vacuoles at a central luminal space in intracellular cord hollowing, or a shared luminal
space between cells in intercellular cord hollowing. [116] Recruitment and trafficking of
vesicles is thought to be mediated by Cdc42, a member of the small Rho GTPase family
of peptides.[117] Empirical evidence of this phenomena is provided by animal studies. Bar
et al have noted the preponderance of relatively ‘seamless’ capillaries in about 15-30%
of capillary cross sections from the rat parietal cortex, and in 50% of endothelial cells in
the renal glomeruli or intestinal villi.[118, 119] These ‘seamless’ capillary segments lack
interendothelial junctions and have been used as evidence for the intracellular vacuole
coalescence model of lumen formation. In our own in vivo studies, we occasionally see
single cell luminal structures in SPEC implant cross sections.[95]
Alternatively, or potentially working in concert with vacuole coalescence,
junctional proteins, such as VE-cadherin, are laterally rearranged in endothelial cells to
allow apical/basal polarity, a process mediated by polarity associated proteins such as
Par3.[120] Sialomucins such as CD34 and podocalyxin like peptide (PODXL) are recruited
to the forming apical membrane of the endothelium, while β1-integrin tethers cells
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peripherally on the basolateral side. [120] Electrostatic repulsion of sialomucins may
initiate lumen formation between luminal surfaces. CD34 also recruits F-actin to the
luminal surface, as well as myosin II. The necessary energy to induce cytoskeletal
rearrangements of the resulting action-myosin complex and move apart apposing
luminal surfaces in the “Polarization model” is supplied by Rho-associated (ROCK)
kinase activity.[121]
While several additional molecular processes may be implicated in lumen
formation, the Cdc42/Rac1 mediated vacuole coalescence as well as the cytoskeletal
rearrangements mediated by ROCK kinase activity are highly dependent on VEGFA/VEGFR2 signaling, suggesting a potential molecular basis behind VEGF-mediated
lumen formation in our spheroids. Cdc42 acts downstream of VEGFR2 activation and
has been reported as a mediator of VEGF/VEGFR2-associated cell-shape remodeling in
endothelial cells. [122] Similarly ROCK kinase activity has been shown to mediate VEGFassociated EC tube formation and angiogenesis.[123]

4.4 Phenotype Changes Associated with VEGF-Treatment of SPECs
Our own research, however, is only partially supportive of a polarization model of
vascular lumen formation under exogenous VEGF treatment. We have previously noted
that cavity formation in the SPECs is anticipated by F-actin distribution, a facet more
clearly seen when implants are treated after at least three days in vitro assembly (Figure
3.4). This correlates with CD34-mediated recruitment of F-actin to a forming luminal
surface in endothelial cords. Additionally, we show an increase in PODXL expression at
early time points (24h and 48h) following VEGF-dosing in SPECs, although at later time
points untreated SPECs begin to demonstrate increased expression of this apical
membrane-associated sialomucin (Figure 4.5). An increased expression of laminin, a
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basement membrane protein, as well as N-cadherin, a junctional protein associated with
endothelial interaction with mural cells as well as connective tissue surrounding forming
vessels, suggests formation of a basement membrane compartment in treated SPECs.
We demonstrate an increase in vWF expression in implants collected after 3 days of

FIGURE 4.5: Western blots of SPECs and VEGF-treated SPECs show differing expression of
PODXL, Laminin, vWF, and N-cadherin (representative WB, n=2). PODXL, a sialomucin
recruited to the apical surface of forming vascular lumens, is expressed at increased levels at
earlier time points in VEGF-treated SPECs. Similarly, Laminin, a basement membrane
component, is increased in VEGF-treated SPECs, as is vWF (vascular endothelial marker) and ncadherin, a junctional marker for adluminal cell interaction. Cdc42, a small Rho GTPase, does not
show changes in expression in treated SPECs.

treatment, associated with increased presence of vascular endothelial cells in some of
the treated implants, potentially due to longer incubation times; however, this does not
appear correlated with an increase in CD31+ cells in implant cross sections, except at 10
ng/mL doses. Global Cdc42 expression does not change across implants; however, we
note that this may not be correlated with differential activation of Cdc42. In future
studies, we will need to examine phosphorylated-small Rho GTPase expression to study
potential VEGF activation of vacuolization and shape/change associated pathways.
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However, insufficient amounts of protein were collected from our spheroids to allow such
as study at this point.

4.5 Cell Death in Treated SPECs
There is very little evidence of VEGF-induced cytotoxicity in literature. However, in
SPECs, there is evidence of cell death and anoikis within forming cavities. TUNEL
(terminal deoxynucleotidyl transferase dUTP nick end labeling) staining of cells was
conducted to probe for DNA fragments associated with cellular necrosis and apoptosis.
TUNEL Stain

Untreated SPEC (D2)
Hoechst
TUNEL+

150 μm

150 μm
TUNEL Stain

Untreated SPEC (D5)
Hoechst
TUNEL+

100 μm

100 μm

FIGURE 4.6: Untreated implants show few TUNEL+ (green) cells throughout
the incubation period, suggesting little cell death in the implants.
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VEGF SPEC (Rx D1-D4)

200 μm

Hoechst
TUNEL+

200 μm

TUNEL Stain

VEGF SPEC (Rx D2-D5)

100 μm

100 μm
TUNEL Stain

VEGF SPEC (Rx D3-D6)

150 μm

150 μm

FIGURE 4.7: There is increased TUNEL+ staining at earlier treatments of SPECs with 50 ng/mL
VEGF. These apparently necrotic or apoptotic cells are concentrated within cavities of the constructs.

TUNEL+ cells were consistently found in 50 ng/mL treated implants (Figure 4.7); this
increase in apparent cell death was not shown to be associated with lowered oxygen
tension due to increased metabolic demand, one potential mechanism for cavity
81

82
50 um

50 um

50 um

50 um

50 um

50 um

200 um

10uM

50 um

50 um

50 um

200 um

50 um

50 um

50 um

50uM

50 um

50
um

50 um

200 um

50 um

50
um

50
um

FIGURE 4.8: 2,4 Dinitrophenol treated (0, 20, 50 uM) SPECs showed increased showed increased disruption of endothelial (cd31+
red) and f-actin (Phalloidin staining green) architecture. Resulting cavitations at high concentrations of the metabolic poison were
not encircled by endothelial lumen or f-actin dense banding as is the case in VEGF-treated implants.

EtoH

formation. In such a scenario, we would anticipate increased expression of hypoxia

inducible factor 1-α, which is released in cells in response to decreased oxygen tension.

Instead, we see little evidence of hypoxia within our treated and untreated implants

(Images Pending). Currently, we are exploring the role of metabolic limitations on

spheroid assembly. In one experiment, SPECs and fibroblast-only spheroids were
treated with 2,4 dinitrophenol, a metabolic poison that preferentially inhibits oxidative
phosphorylation (by collapsing the proton motive force used to produce ATP, the crucial
metabolic substrate of cells). In these studies, cavities did emerge within the implants, as
was seen in VEGF treatment; however, these cavities were not lined with endothelial
cells and did not demonstrate notable changes in cells and cytoskeletal patterning that
we have noted in VEGF-treated spheroids (Figure 4.8). We cannot completely rule out
the possibility of a metabolic component to spheroid assembly in an exogenous VEGF
field; study of cellular metabolism in tissue engineering, while outside the scope of this
dissertation, is an active field of research in our laboratory.
Another potential rationale for cell death within our treated-SPECs is that
endothelial cells do not normally produce an extracellular matrix, and cells at the core of
endothelial clusters would be relatively distant from fibroblast-derived matrix. This form
of cell death is termed anoikis, or apoptosis due to inappropriate or inadequate adhesion
of a cell to extracellular matrix or nearby cells.[124] In embryological development, many
cells undergo a process of epithelial-to-mesenchymal transition (EMT), where cells
undergo a reorganization of junctional proteins, detach from other epithelial cells and
matrix, and invade into surrounding tissue.[125] These cells can be subject to anoikis
when displaced for too long a period. A careful coordination of EMT and anoikis
accounts for the formation of hollow glands. The acinar lumens within glands are
described as sack-like cavities that have undergone controlled multicellular cavitation
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through anoikis.[125] Notably, the cells surrounding these cavities retain functional
apical/basal polarity. We distinguish this process from previous intra/intercellular canal
formations by describing this model of lumen formation as the “Anoikis Model.”
Dynamics of cell death by anoikis was assayed by plating a low-density mixture of 1: 4
endothelial cells and fibroblasts (representing SPEC cell fractions) on adherent

0 ng/mL

Graph Place
Holder

0 ng/mL

300 μm

300 μm

10 ng/mL

Graph Place
Holder

10 ng/mL

FIGURE 4.9: 1:4 mixture of
endothelial cells and Fibroblasts
were coated on non-adherent (left)
300 μm and adherent (right) plates, and
stained with Trypan Blue vitality
dye after 24h of incubation.
Vitality dye uptake was minimal in
plated cells, but increased with
increased VEGF treatment on
adherent
plates,
with
dye
localizing to the center of the
forming Endothelial/ Fibroblast
300 μm Spheroids.
Larger
spheroids
formed in non-adherent plates with
increased VEGF dosing

300 μm

100 ng/mL

100 ng/mL

300 μm

1000 ng/mL

1000 ng/mL

300 μm

300 μm
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(fibronectin coated) and non-adherent (coated with Anti-adherence rising solution;
STEMCELL Technologies 07010) wells (5,000 cells per cm2). By comparing cell death
(0.5% Trypan Blue vitality dye uptake) with and without VEGF-treatment in adherent and
non-adherent plates, we were able to determine whether anoikis caused appreciable cell
death in a 24h period (Figure 4.9). Plated cells showed little vitality dye uptake with 01000 ng/mL VEGF dosing. On the other hand, VEGF treated non-adherent cells showed
a dose-dependent increase in spheroid forming behavior, with agglomeration of smaller
spheroids into larger constructs at higher doses (100-1000 ng/mL). Accompanying this
observation was an increase in vitality dye uptake in non-adherent cells, with dye
concentrating at the center of the forming spheroids.

4.6 Cellular Potts Modeling Framework

Contact/Adhesion Energy
Optimization

VEGF
Diffusion
Gradient

Endothelial Cell Activation
Proliferation
“Polarization”
Model of Lumen
Formation”

“Anoikis” Model
of Lumen
Formation

2D Cell Environment
FIGURE 4.10: Proposed Modeling Framework for SPEC Self-Assembly within
VEGF Field

With the preceding in vitro experiment-derived insights in mind, we can began
constructing a computational model of spheroid assembly. The basic framework of our
cellular self-assembly and lumen formation simulation is summarized in (Figure 4.10).
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Using a two-dimensional view of spheroid assembly, we wish to model the following: (1)
Contact/Interfacial Energy Optimization in Tissue (2) VEGF activation of Endothelial
Cells (3) Mitosis (4) Lumen Formation. Additionally, the cells are modeled in an

FIGURE 4.11: Hexagonal lattice representation of a 1:4 mixture of inactive endothelial cells
(green) and fibroblasts (blue). 2D spheroid is bound by a wall constructed out of fixed
(unmoving) pixels that have a high interface cost (i.e. are nonadherent)

exogenous VEGF field; thus, diffusion of molecules of VEGF requires utilization of a
partial differential equation (PDE) solver, as discussed in Chapter 3. Contact energy
optimization and PDE solver modeling utilizes an open-source simulation framework,
CompuCell3D, developed by Glazier et al [126]. The remaining modeling components
were programmed using Python, with some mathematical insights gained by programs
developed in MATLAB.
The modeling framework employed for contact energy optimization in our
simulations invokes the Cellular Pott’s model, also known as the Glazier-GranerHogeway (GGH) model.[126] This model was formulated to simplify complex cell and
tissue behavior into manageable set of parameters, working on a lattice of pixels. In our
case, we use a hexagonal lattice to increase the pixel adjacencies and more realistically
simulate cell-cell interactions than in the typical Euclidean rectangular lattice. Each pixel
is assigned a cell-identifier and the user-defined parameters defining the cell type (e.g.
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endothelial cell or fibroblast). All the pixels with the same cell-identifier comprise a single
cell. Operations can be conducted on a pixel (subcellular) level, cellular level, and cell
cluster-level, with a Python dictionary component assigned to the pixel to allow
assignment of different hierarchical designations. Our model, for instance, organizes
each pixel by cell and a cluster of nearest-neighbor cells (useful later in modeling
“Anokis”). Figure 4.11 shows an example of an initial organization of endothelial cells
and fibroblasts in our 200x200 pixel (400 x 400 um) lattice structure in a VEGF field. In
the GGH model, the physical behavior of cells (e.g. movement and deformation) is
guided by evaluating the following equations (derived by Swat et al[126]) at each pixel:

The equations represent the effect energy (H) associated with a pixel assuming the
properties of a nearby pixel. A pixel-copy is a visualization of the fluid boundary changes
between adjacent cells. To better represent biological processes, a pixel-copy has some
probability of success, rendering it a stochastic process. As indicated in (Figure 4.12),
the first summation term calculates the product of an energy cost term J (represented as
a matrix of contact energies between different cell/material types) and a component
representing whether a pixel is close to the surface of a cell. This term ensures that a
pixel within the interior of one cell does not adopt the properties of an adjacent cell by
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Energy increases with fluctuation from Vt with a set tolerance (lambda)

FIGURE 4.12: Calculation of the Hamiltonian or the effective energy cost of
changing a cell’s pixel properties to that of a nearby cell. The first sum is the
energy cost of forming a boundary between two cells or materials. The second
sum establishes the cost of deviating from a set volume (expected cell volume).

chance. Intuitively, the contact energy cost J, for instance, is set to a high value between
the agarose wall bounding the spheroid and a cell, since the cells should not adhere to
this wall. The energy cost of an activated endothelial cell to another activated endothelial
cell, on the other hand, is set to a low comparative value in order to enable modeling
endothelial condensing phenomena observed in our in vitro studies. The second
summation term in the model, on the other hand, provides a volume constraint per cell
type (Vt, set to 25 pixels representing an area of 100 um2 for inactive endothelial cells,
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Metropolis Algorithm
FIGURE 4.13: (Top) The CompuCell
3D Algorithmic architecture (Figure
from Swat et al, Methods Cell Bio, 2012)
invokes the Metropolis algorithm at each
Monte Carlo Step before running our
custom
modeling
functions
(“steppables”).
(Right) A successful pixel-copy can be
visualized as territorial acquisition of
lattice space by one cell, and loss from
another cell.

for instance) with an allowable tolerance factor (λ= set to 4). In other words, a pixel-copy
is unlikely to be successful if it increases or decreases a cell size well past an estimated
ideal volume. The Metropolis algorithm (Figure 4.13), represents the probability of a
pixel-copy given an effective energy cost (H), and is used to stochastically model cell
boundary changes across the entire lattice during one Monte Carlo Step. A Monte Carlo
step (MCS), in this application, refers to one iteration of all the stochastic modeling
functions (representing the Python-based modeling blocks presented in Figure 4.10) as
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well as running pixel-copy attempts. An MCS can serve as a dimensionless unit of time
in a simulation. We generated modeling parameters with the expectation of running 1
MCS per 10 seconds of simulated time across 3 days. Each simulation of spheroid selfassembly, thus, runs 25,920 MCS before terminating.
The Cellular Potts framework, if used without any other modeling considerations,
is an approximation of the differential adhesion hypothesis by Foty et al.[33] As such, it is
only truly applicable to embryological cells and cells cultured in vitro without the complex
cascade of in vivo biological signaling events. It can never faithful replicate active
biological processes. Nevertheless, we anticipate when an overriding input, such as
exogenous VEGF overdose, overcomes more subtle biological processes, the
differential adhesion hypothesis can become a powerful predictive tool.

4.7 VEGF-Activation of Endothelial Cells
Conceptually, our model of VEGF-activation of endothelial cells is relatively simple. An
endothelial cell within our agarose-bounded lattice space has a probability of changing
from an “Endothelial” cell type, with associated contact energy parameters, to an
“Activated” cell type. The activated cell-type has a decreased effective energy cost
associated with making a contact with another activated endothelial cell, representing
loss of contact-inhibition and increased clustering behavior. This probability is a function
of VEGF. The vendors (R&D Systems) for rhVEGF165, provided a dose-response curve
(Figure 4.14), with a half maximal effective concentration (EC-50) at 1-6 ng/mL and a
minimal and maximal response at <1 ng/mL and >10 ng/mL respectively. Given a
maximal clustering response in our in vitro assays was found to be between 50-100
ng/mL and a minimal response between 0-1 ng/mL, we shifted the curve slightly,
selecting an EC-50 of 10 ng/mL. Thus, at 10 ng/mL, 50% of endothelial cells should
attain an “active” or condensing phenotype.
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Algorithmically, VEGF-activation becomes a little more complex. Monte Carlo
simulations must be stochastic with time. The concentration/response curve provides an
equilibrium state response without any activation kinetics. To model stochastic VEGF
activation in time while maintaining biological verisimilitude, we implemented a Hidden
Markov Chain Monte Carlo (HMCMC) algorithm (Figure 4.15). In this algorithm, each

FIGURE 4.14: Concentration vs Response Curve of
rhVEGF 165 (from http://www.rndsystems.com). The EC50 of the curve is between 1-6 ng/mL.

cell is provided 100 receptor loci (representing 100% surface VEGFR2 receptors) that
can transition between “on” and “off” states with calculated transition probabilities. The
probability equations in (Figure 4.15) are analogs to the association rate equation and
dissociation rate equations for receptor-ligand interactions. Increased VEGF
concentration increases the “on”-state probability of a receptor locus, while increased
“on”-states, representing filled receptor loci, increases the probability of a receptor locus
adopting an “off” state. At a certain threshold of “on” receptors (52%), an endothelial cell
was transformed into an activated endothelial cell. Subsequent inactivation of the cell
was also possible, with enough receptor dissociation (48%). On-off transition rate
constants and active-inactive thresholds were calculated graphically using Matlab by
adjusting parameters until an equilibrium-state dose response curve (with EC-50 at 10
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Receptor Locus:
𝑃𝑜𝑛→𝑜𝑓𝑓
On

Off
𝑃𝑜𝑓𝑓→𝑜𝑛
𝑃𝑜𝑓𝑓→𝑜𝑓𝑓 = 1 − 𝑃𝑜𝑓𝑓→𝑜𝑛

𝑃𝑜𝑛→𝑜𝑛 = 1 − 𝑃𝑜𝑛→𝑜𝑓𝑓

𝑃𝑜𝑛→𝑜𝑓𝑓 = 0.0001 × ሾ𝑉𝐸𝐺𝐹ሿ ×

𝑃𝑜𝑛→𝑜𝑓𝑓 = 0.001 ×

100 − # 𝑜𝑛
100

# 𝑜𝑛
100

% Cells Active

M.C.S (10 s)
FIGURE 4.15: A 2-state Hidden Markov Chain Monte Carlo algorithm is used to model a receptor
locus status (on/off). Probabilities of transition are analogous to association and dissociation rates in
receptor-ligand binding kinetics. Rate constants and threshold number of receptors for active/inactive
states selected to attain 50% cell activation after ~12h incubation time at a 10 ng/mL dose

ng/mL) was attained after 12 hour of simulation time (essentially after cells have settled
into the agarose wells).
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4.8 Polarization Model and Anoikis Model of VEGF-treated SPEC Lumen
Formation
The final modeling consideration in our simulation is lumen formation. We have
previously discussed evidence of two potential lumen formation models in VEGF-treated
SPECS. One is the “Polarization Model” where a luminal space is created by active
reorganization of junctional proteins and electrostatic repulsion of sialomucins at the
luminal interface. The other is the “Anoikis Model”, where cells without nearby
attachments to extracellular matrix die and leave behind a void within the constructs.

FIGURE 4.16: Polarization as modeled in computational simulation. Activated
endothelial cells split into basal and luminal surfaces, with an updated set of contact
energy traits

The “Polarization” model is depicted in (Figure 4.16). An activated endothelial
cell in our Cellular Potts lattice has a certain probability of activating cell polarization
pathways. When the cell is activated, it is divided into two subcellular compartments
representing a basal, and luminal surface. The void space associated with the luminal
surface is an assumed factor and not visually depicted as empty space since the space
should not be collapsible. Conceptually this means that the space would not exist if not
for energy dependent processes such as vacuole exocytosis or ROCK mediated
contraction of surface actinomyosin complexes. If we modeled the space as “Medium”
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as we have the space surrounding the forming constructs, the luminal space would
collapse. The subcellular luminal compartments preferentially coalesce with other nearby
luminal compartments; again, this is mediated by a change in contact energy associated
with the “Luminal EC Surface”-type identifier.
The “Anoikis Model” is a work in progress as a few nonbiological abstractions are
made to allow hollow lumen formation. The model involves an analysis of each cells
nearest-neighbor. Once an endothelial cluster has formed, a nearest-neighbor search for
cells in the center of the cluster will reveal no nearby fibroblasts. The cell is then flagged
as unattached to the stromal matrix of the SPEC construct and, after a few hours, is set

FIGURE 4.17: Computational model of anoikis. After activatedendothelial cells cluster, cells in the interior without a fibroblast nearestneighbor are flagged as anoikis-sensitive. In time, these cells die and
the endothelial cells surrounding the dead cells are inactivated.
to “sick/dead” cell state. While the steps described thus far are relevant to anoikis, the
sick cells would be rapidly ejected from the forming spheroids without additional
modeling constraints. This, in fact, is what we would expect to happen in soft tissue, as
dead cells do not have the capacity to form cellular adhesions and would be sorted to
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FIGURE 4.18: Computational model of VEGF Dose Dependent Lumen Formation. (Green:
Inactive Endothelial; Blue: Fibroblasts; White: Basal surface of lumen; Purple: Apical Surface of
Lumen)

the periphery of a spheroid according the differential adhesion hypothesis. To prevent
this from happening, we switch the nearest-neighbor endothelial cells to sick cells to an
inactive endothelial cell state. These endothelial cells are stripped of their capacity to
cluster and physically crowd out the resulting dead cells. Thus far, there is no biological
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rationale for this step; however, within the computational framework we have
established, this additional process appears to be a plausible way that multicellular
cavitation could result in an endothelium-lined luminal space. Whether or not this
simulated phenomenon translates to biological reality requires real experimentation.
Ultimately, the chief purpose off in silico experimentation is to generate similar
hypotheses for in vivo or in vitro experimentation.
The simulation results of the Polarization Model at 1, 10, and 50 ng/mL exogenous
VEGF dosing are depicted in (Figure 4.18). The simulation successfully reproduces the
main findings of the in vitro experiments: VEGF-treated SPECs produce a dosedependent increased in number of lumen and diameter of lumens.
3.1.1 Generating Candidate Spheroid Treatments using the Polarization Model
Reproducing lumen formation in SPECs treated with VEGF in computational
simulations provides a convenient platform for in silico experimentation. By identifying
tunable parameters within our computational framework, we can design a series of
experiments to develop a regression model. From this regression model, we can
extrapolate potential candidate treatments that would improve lumen formation in our
scaffold-free constructs. There are, of course, three significant limitations to our
computational model that must first be broached: (1) Our computational model is built on
the foundations of VEGF-induced cell clustering, so improved lumen formation will
always have to be contextualized around a baseline VEGF-treatment; (2) We are
modeling a finite list of parameters and not all treatments to improve lumen formation will
have functional analogs among our model parameters; (3) We are modeling behavior of
two cell types, and excluding consideration of important vascular components such as
mural cells. Additionally, an ideal set of treatment candidates would require a large
library of small molecules with documented effects on vascularization. To the best of our
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knowledge, no such convenient repository of small molecules has been created. To
contend with these limitations, we first performed a literature search of growth factors
and biological signaling molecules associated with fibroblast and endothelial behavior.
We then identified studies that explicitly compared the effects of these factors to VEGFA treatment and mapped these effects to tunable parameters in our computational
model. Table 4.1 lists the outcomes of this search.

Name
VEGF 121

TABLE 4.1: Potential Candidate Treatments
Parameter
Description
- Decay Rate
Fibrin-binding variant
(VEGF 121) shows lower
levels of constant receptor
activation but can maintain
a more controlled pattern of
vessel formation. May
ensure ECM dense regions
receive preferential VEGF
activation[127]

FGF-1

-Activated EC-Fb
contact energy
-Threshold of Response

FGF-2

-Activated EC-Fb
contact energy
+Mitosis

FGF-1 induces protease
activity (plasminogen
activator [128] Higher affinity
of endothelial cells to ECM
proteins, and VEGF
potentiating effect
FGF-2 induces protease
activity (plasminogen
activator, 2.5x basal, 3x
VEGF in this scenario,
although VEGF may have
alternate methods of
inducing ECM
degradation)[128]
Induced mitosis (4-5x
basal)[128]

TGF-β

-Fb-Fb contact energy
+Mitosis

Angiopoietin 1

-Nearest Neighbor
Requirement for Anoikis
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Promotes ECM deposition
and integrin receptor
upregulation.[128]
Agonist that induces
pkB/Akt pathway for EC
survival[115] Historically
“proangiogenic”

Angiopoietin 2

+Mitosis
+Activated EC-Actviated
EC contact Energy

PDGF-BB

+Mitosis

Heparin/Heparin sulfate
proteoglycan

-Threshold of Response
+Half-life

Vestaine-A

-EC-EC Contact Energy

PIGF (placental growth
factor)

-Threshold of Response

Proteases: plasmin and
MMPs

+Fb-Fb contact energy
+Activated EC-Activated
EC contact energy

Smoothened peptide
agonists

+Polarization Rate
+EC-EC

Shh (Sonic Hedgehog)

+Polarization Rate
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Reduced endothelialendothelial adhesions due
to reduced VE-cadherin.[129]
Proangiogenic effects
requires priming with
VEGF.
Mitotic effect 18 fold (vs 8
fold for VEGF)
Induced mitosis (2-3x
basal)[128]
Binding stabilizes
VEGF/VEGF-R binding and
active conformation of
VEGF. Prevents
degradation of VEGF.
Enhances potency of
angiogenic response in
ECM with type-I
collagen[130]
When added to VEGF 50
ng/mL, suppressed vessel
leakiness. Activates
MEK1/2 and PI-3K
pathway independently of
VEGF. Improves EC barrier
function.[131]
Potentiates VEGFA/VEGFR2 response by
competitively binding
VEGFR1.[132] [133]
Degrades ECM, increasing
movement potential of EC
(and Fb). Also break apart
VE-Cadherin bonds. [134]
Activation of smoothened
appears necessary in
uniluminal formation for gut
lumen in zebrafish.[135]
Involves recycling and
fusion of PODXL
containing vesicles into
apical space resemble
vascular lumen formation
process.
PODXL induces luminal
repulsion via electrostatic
forces.[136]
Induces apico/basal
polarization, and

Slit2 (Robo-slit signaling)

-EC-EC
+EC-Fb
+Polarization Rate

associated with increased
lumen count. [65]
Cooperates with VEGFA to
enhance
neovascularization via
front/rear polarity (not
pertinent to lumen
formation model).[137, 138]
EC-EC adhesions are
weakened, but EC
invasiveness is also
decreased
Enhanced relative vessel
diameter (mechanism not
explained). Plays role in
cardiac lumen formation
(via apical polarity, and
cell-cell repulsion. [137, 138]

As a result of this literature search, the following 9 factors were selected for
tuning (+/- from a baseline 10 ng/mL VEGF Treatment) in our lumen formation model: (1)
Activated endothelial-Activated endothelial contact energy; (2) Activated endothelialfibroblast contact energy; (3) Fibroblast-Fibroblast contact energy; (4) Proliferation; (5)
VEGF Decay Rate; (6) VEGF Diffusivity; (7) Threshold of Response; (8) Polarization; (9)
Time of treatment, which was set to either at the beginning of the simulation or at 1.5
days (half the simulation time). Additionally, we established a set of criteria for an
optimal lumen arrangement in our constructs,
0, 𝑛 < 1
𝑛 − 1 𝑟1
𝑛(# 𝑙𝑢𝑚𝑒𝑛) = {(
) , 1 ≤ 𝑛 ≤ 16
16 − 1
1, 𝑛 > 16
0, 𝑎 < 201 𝑢𝑚2
𝑎 − 200 𝑟1
𝑎(𝑙𝑢𝑚𝑖𝑛𝑎𝑙 𝑎𝑟𝑒𝑎 = 𝑛 ∙ 𝑝) = {(
) , 200 ≤ 𝑎 ≤ 800
800 − 200
1, 𝑎 > 800
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0, 𝑑 < 5 𝑢𝑚

d(𝑚𝑒𝑑𝑖𝑎𝑛 𝑑𝑖𝑎𝑚𝑒𝑡𝑒𝑟) =

𝑑 ۓ−5 𝑟2
ۖ ቀ ቁ , 5𝑢𝑚 ≤ 𝑛 ≤ 8 𝑢𝑚
8−5
𝑟2

۔ቀ40−𝑑ቁ , 8 𝑢𝑚 ≤ 𝑛 ≤ 40 𝑢𝑚
ۖ 40−8
ە
0, 𝑑 > 40 𝑢𝑚

r (𝑠𝑢𝑚𝑚𝑎𝑟𝑖𝑧𝑒𝑑 𝑟𝑒𝑠𝑝𝑜𝑛𝑠𝑒) = (.55 ∗ 𝑎 + .3 ∗ 𝑛 + .15 ∗ 𝑑);

Time-weighted Objective Function 𝜑 = σ𝑛𝑖=1:3, 𝑗=1:4 𝑡𝑖 ∗ 𝑟𝑖 ; t-weights are .15, .3, .55
respectively

We anticipate that 16 capillary-sized lumens spread across a 300-um diameter construct
will ensure adequate perfusion, with an average distance between the capillaries <50
um. This recalls the previously discussed diffusion limit of oxygen, usually approximated
at greater than a few hundred-micron thickness of tissue. Optimal vessel diameters were
selected between a range of 5-40 um, with 8 reported as the average diameter of
capillaries in mammalian soft tissue[139] and 40 being the maximal diameter of capillaries,
seen in liver sinusoids. Larger vessels require the support of perivascular cells (as
previously discussed in Chapter 3); therefore, we anticipate these structures would
collapse if the constructs were mechanically stressed. The summarized response metric
r incorporates the overall perfusion area as the most heavily weighted term, principally to
devalue simulation scenarios where many small peripheral lumens form in a construct
cross section. The overall time-weighted objective function evaluates lumen formation at
1,2, and 3 day of simulation time. While the final outcome after three days of treatment is
given the highest weight in the objective function, we reward early vascular development
by summing the day 1 and day 2 summary responses with lighter weights (.15 and .3).
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The most optimal simulation should result in an objective response approaching a
maximum of 1.
While a full-factorial experiment at 3 levels (+,0,-) except for time (0,+) would
allow us to evaluate a regression model, this design method is computationally
expensive, requiring 2x38 or 13122. We conducted a series of experiments using a doptimal design to allow statistical models to be evaluated using fewer experimental runs.
D-optimal design is an experimental design that seeks to minimize the covariance of

FIGURE 4.19: (right) The experimental run with the highest objective response shows a diffuse
distribution of large capillary-caliber lumen like structures (left) A less optimal simulation shows
small peripheral lumens. The 5 most significant regression terms and the associated coefficients
(scaled to -1, 0, +1 response) are tabled below
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parameters by maximizating the determinant (XTX-1) of the design matrix X (columns are
regression model terms and rows are specific treatments). The design was evaluated
using Stat-Ease Design-Expert® software and resulted in 67 experimental runs. The first
round of regression analysis identified 5 factors (and associated quadratic terms and
mixture terms) as important, including EC-EC interactions, Fb-Fb interactions, VEGF
decay rate within tissue, Threshold of Response to VGF, and Polarization. An additional
round of regression analysis on these terms alone resulted in three factors that had the
most significant impact on the model: EC-EC contact, Fb-Fb contact, and Threshold of
Respone. The results of the simulations are indicated in (Figure 4.19).
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5 FUTURE DIRECTIONS
5.1 SPEC Simulation Results and Fibroblast-Fibroblast Interactions
From our candidate treatments table (Table 4.1), a handful of potential adjuvant
treatments to the VEGF meet the criteria of decreasing contact energy cost for
endothelial-endothelial contacts (VEGF, Vestaine A, Slit2) fibroblast-fibroblast interfaces
(such as TGFβ) and decreasing the receptor threshold of response to VEGF (such as
FGF-1, PIGF). We can envision a series of multifactor experiments where we treat
SPECs and other 3D cocultures with a cocktail of these factors in order to induce lumenformation. Ideally, predosing constructs will have a continued effect in anastomosis of
formed spheroids in vitro. By focusing on the three principle contributors to our
regression model, we note only one parameter appears to change entirely independent
of VEGF-A pretreatment: fibroblast-fibroblast interface energy costs. While factors such
as TGFβ can improve stability of the fibroblast compartment in spheroids by increasing
deposition of ECM, contributing to tissue fibroplasia,[140] allowing early fibrodysplastic
changes in tissue might actually make in vivo penetration of this tissue more difficult
having an overall negative effect in vascularizing implanted tissue. We are not, however,
limited to TGFβ family growth factors in approaches to manipulating the fibroblast
compartment. This factor was identified when a literature search was conducted on
known factors influencing vascularization in the context of VEGF treatment; we can,
instead, focus on factors that have an effect in fibroblast-fibroblast adhesion with an
unknown effect on angiogenesis. Given that fibroblasts can exist as a syncytium in
certain organs such as the heart,[141]we anticipate that gap junctional proteins have a
functional role in fibroblast intercellular adhesivity. This has been experimentally
validated in studies such as those conducted by Ko et al., where gap junction molecules
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such as connexin43, as well as adherens junction molecules such as cadherins, were
recruited to intercellular contacts between fibroblasts.[142] Connexin43 recruitment to
intercellular contacts among fibroblasts is of interest to our laboratory as we have
conducted studies using modulators of connexin43 channel and hemichannel formation,
including the novel peptide connexin 43 mimetic peptide juxtamembrane 2 (JM2).[143]
While our previous studies have centered on the anti-inflammatory properties of JM2
mediated by decreased hemichannel formation and consequent decrease in purinergic
signaling in damaged cells, we have long postulated that connexin43 modulators may
have role in angiogenesis. This may be due to the role of purinergic signaling in
processes such as hemostasis[100], but, from our simulation results, we may also
consider the effect on intercellular contacts in fibroblasts within forming granulation
tissue or a capillary bed. Thus, in future experiments we expect to treat SPECs with
connexin modulators such as JM2 with or without additional pro-lumen forming agents
(such as VEGF) to see if modulation of the fibroblast-fibroblast intercellular signaling can
change the lumen formation patterns in our SPEC capillary network in vitro.

5.2 Re-scaling the SPEC Model
Additionally, we expect to identify and address the dimensional limits of the SPEC
model. Poor tissue vascularization imposes a dimensional limit on tissue engineering
technology due to a mismatch in oxygen consumption and oxygen availability. Most of
our previous work, however, does not address the variable of tissue thickness, focusing
instead on rod shaped SPECs of fixed linear dimensions. These constructs when formed
following a 3-day incubation period had variable diameters, but few approached
dimensions larger than a 500-um radial thickness. A true test of successful
prevascularization and lumen formation would include the ability to support larger
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dimension SPECs in vivo; however, this would not be feasible with our current
methodology of allowing high density cell suspensions to aggregate into spheroids.
The issue of scale is further exacerbated by difficulties in scaling our probabilitybased computational models. Spheroid modeling by differential adhesion hypothesis
appears reliable with a relatively small number of cells that are, initially, free to move and
reorient during self-assembly. However, we cannot expect our model to faithfully
recapitulate the behavior in a larger pool of cells. At increased scales, other physical
phenomena, such as density-based segregation of cells or packing space may start
impacting tissue assembly. We can attempt to model this new set of phenomena for
tissues of different dimensions; however, this model may not be extrapolatable to the
smaller scale SPECs. This, in fact, mimics the scale-based distinctions in vessel
formation in vivo. Smaller capillary based structures can form relatively spontaneously
from a granulomatous mix of endothelial cells and fibroblasts, but larger structures such
as arteries and veins may require inosculation of smaller vessels and architectural
support with the addition of perivascular cells as well as fibrous connective tissue. In
short, for both in silico and real-life scenarios, phenomena guiding small vessel
formation in smaller tissue differs from the phenomena guiding vessel formation in larger
tissues.
Fortunately, we are not confined to a completely unguided self-assembly process
in tissue engineering of tissue. In future aims, we can utilize hybrid approaches where
small self-assembled building blocks (such as the SPEC) fuse into larger structures
either with the guidance of a scaffold (hybrid scaffold-free/scaffold-based technology) or
using molds or sheet-based bioprinting approaches. Fusion of prevascular spheroids
and preservation of vascular motifs such as unlimunal formations has already been
observed in studies by our collaborators, such as Drake et al.[144] We envision using a
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bioprinting based approach, where pre-treated or untreated SPECs are allowed to fuse
into larger structures. Such an approach simplifies modeling into a two-scale approach.
We focus on self-assembly kinetics in each of the modular building blocks, while
focusing on fusion behavior at interfaces. Ideally, this model will scale with larger and
larger tissues. What remains to be seen, however, is whether such an approach will
result in a structure that is stable in vivo.

5.3 Role of Inflammation and Immunity in TEC Vascularization
As mentioned in Chapter 1, this thesis and the related projects do not specifically
address the inflammatory arm of implant destruction. However, we cannot adequately
explore vascularization of TECs without exploring inflammation and immunity. The past
decade has seen many studies that challenge the traditional vessel formation paradigm
in which endothelial cells form inert blood barriers within tissue. Endothelial cells
participate in both non-specific innate immunity and antigen-specific adaptive
immunity.[145] We may need to recontextualize in vivo SPEC vascularization as a function
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of angiogenesis, inflammation, and the interplay between the two broad categories of
signaling processes.

6 h SPEC, Hoechst, Complement C3, vWF

12 h SPEC, vWF , Hoechst, Complement C5b-C9 (MAC)
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FIGURE 5.1: (Left) Complement C3 deposition evident on exterior of silicone implant and
exterior/interior of SPEC. C3 deposition on SPEC tracks with endothelial organization, as
demonstrated by sister sections taken at 6-24 h. (Right). C5b-C9 complement deposition associated
with membrane attack complex formation (MAC) also coincides with microvessel bands within spec
from 12-24h period. Muscle-Implant interface indicated by white curve.

The first issue that must be addressed is the potential of poor tolerogenicity of
implanted endothelial cells. While we chose to focus on early signs of angiogenesis in
our SPEC studies to avoid complications of the later phases of the adaptive immune
response (acute and chronic), our choice to implant human cells into Sprague Dawley
rats poses a challenge in preventing a host-response to xenobiotic material. We have
shown a rapid host immune response between 6-24h (Figure 5.1 and Figure 5.2), with
increased deposition of complement proteins tracking with vessel development in the
implanted constructs and increased recruitment of myeloperoxidase positive cells to the
host-implant interface at 12-24h. These immune processes are analogous to those
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expected during a sterile inflammatory response; however, we must exclude a possibility
of a foreign body response or existence of preformed antibodies to xenobiotic
substrates.

6h
100 μm

24h

100 μm

Hoechst, anti-Myeloperoxidase pAb

FIGURE 5.2: Recruitment of myeloperoxidase positive cells (green) to the implant
interface appears to peak at 6h following implantation. Myeloperoxidase pervades
implant in 6h-24h time period.

One potential approach is to create mouse cell derived SPECs from the C57/BL6
background and implant them into syngeneic animals. This approach has been difficult
as we have not been able to sustainably culture explanted mouse endothelial cells even
after adipose digest, lung tissue mincing, or aortic ring culturing. Explanted mouse
endothelial cells do not appear to reliably expand in culture past a couple passages,
making developing a scaffold-free implant highly resource-intensive. Furthermore,
mouse endothelial cells are distinct from human endothelial cells, especially with regards
to immune function. Human endothelial cells contain the costimulatory surface molecule
CD58 unlike mouse cells, which, alongside class II major histocompatibility complex
(MHCII) molecules enables activation of effector T-cells in a host. Use of a murine
model, thus, excludes analysis of this potential confounding role of immune systems on
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tissue endothelialization. Rats, by contrast, do contain CD58 analogs, albeit with lower
binding affinities than their human counterparts.[146] Thus, an alternative approach is to
implant cells into SCID (severe combined immunodeficiency) rats [147], lacking B, T, and
NK cells necessary to initiate most adaptive immune responses that may involve host
species mismatch. This approach will allow us to repeat SPEC vascularization dynamics
studies with a largely unaltered methodology and will likely encompass our first
approach to broaching issues with immune compatibility of vascular constructs.
We can also modulate the tolerogenicity of implanted human endothelial cells in
host animals (include non-autologous transplant in humans) using available technologies
to genetically manipulate non-transformed cells. One method invokes CRISPR/CAS9
technology, where an endonuclease Cas9 is guided by a short RNA guide sequence to
introduce site-specific double-strand breaks in DNA.[148] Recently, this approach has
managed to generate stable genetic alterations of endothelial colony forming cells from
cord blood, which are differentiated cells that resemble HUVECs. This technique has
been used to introduce splice variants of CIITA (MHCII transactivator) that result in lossof-function.[149] This, in turn, has reduced IFN-γ-induced expression of MHC II without
impacting formation of stable EC-lined vessels in SCID background mice, thus enabling
reduced EC-mediated immunogenicity without impacting vascular function.[149] We see
CRISPR/CAS9 as a potentially powerful tool to interrogate specific arms of the immune
system and identify their role in vascularization and survival of implanted endothelial
structures. Introduction of loss-of-function mutations such as specific splice variants of
CII transactivators or less specific camouflaging polymeric motifs (e.g.
methoxypolyethylene glycol[150]) may help attenuate the adaptive immune response
associated with implantation of SPECs.
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We cannot discount the role of the innate immune system in both inhibiting and
driving the vascularization response. In fact, there is evidence that an active innate
immune system is essential for rapid, albeit unstable vascularization of tissue. Damage
associated molecular patterns (DAMP) associated with surgical trauma and TEC
implantation may accelerate inflammatory angiogenesis. DAMP activation of Toll-like
receptors such TLR3 have been shown to induce HIF-1α activation and, consequently
VEGF secretion.[151] Reactive-oxidant species released in sterile inflammation (e.g.
released from recruited neutrophils) can oxidize damaged cell membrane phospholipids
and produce molecules that induce neovascularization through the TLR1/TLR2
pathway.[151] Another aspect of both the innate and adaptive immune system,
complement proteins, have a wide array of functions that are correlated with
vascularization. Complement activation (C3a and C5a) can result in proangiogenic
macrophage activity.[152] Conversely, binding of C3aR and C5aR on monocytes causes
anti-angiogenic response (increase in sVEGFR1 which inhibits angiogenesis). [153] Decay
accelerating factor DAF (CD55) is upregulated by VEGF induction (i.e. VEGF protects
endothelium during chronic inflammation resulting in inflammatory angiogenesis).[154]
Also, C1q deposition induces permeability of EC monolayer and has mitogenic effect on
EC by promotes tube formation. [155]. Vessel formation defective in C1q-deficient mice
and rescued with exogenous C1q administration.
The list of targetable surface molecules associated with DAMP and complementassociated processes is lengthy and can produce numerous experiments associated
with TEC vascular development. We can attempt to introduce genetic alterations using
CRISPR/CAS9. Sampson et al., for instance , have demonstrated a Cas9 dependent
system in Franceisella novicida bacteria that enables evasion of the innate immune
inflammasome formed downstream of toll-like receptor activation.[156] This process might
potentially be recapitulated in extracted, differentiated human cells, reducing activation
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of toll like receptors in implanted cells. Release of DAMPs such as ATP, on the other
hand, can be modulated by factors such as JM2 and ACT1.[26] Existing inhibitors of the
complement system, on the other hand, can be employed to attenuate complementmediated inflammatory response. The effects of these innate system modulators have
not been formally studied in the context of implant vascularization and will certainly form
a strong basis for future strategies to improve TEC engraftment.

5.4 Conclusion
The applications of a fully vascularizable SPEC implant are numerous. We have
already begun work on augmenting dressings to include SPEC-based layers to aid in
vascularization of ulcerative wounds, such as those resulting from chronic pressures
associated with hospital bed rest. In past work, we have attempted to introduce a
payload of parenchymal tissue, such as pancreatic islet cells, renal cortical cells, and
skeletal muscle tissue into the SPEC design. While these applications have benefitted
from the provided endothelial-fibroblast mixture, with increased islet cell and renal cell
survival, and increased activation of satellite cells for recovery of muscle tissue, we
envision that the applications would benefit significantly from rapid development of a true
capillary bed within 24h of implantation. Ultimately, this will be an ongoing process,
which will involve continued cycles of in vivo experimentation, in silico hypothesis
generation, and in vitro design adjustments, until a clinically viable product is
manufactured.
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6 GENERAL METHODS
6.1 Primary Human Cell Culture
Two primary human cell lines were principally used in most experiments included in this
thesis: primary normal adult dermal fibroblasts (NHDF-Ad, ATCC® PCS-201-012) and
primary human adipose microvascular endothelial cells (HAMEC, ScienCellTM 7200).
Normal human dermal fibroblasts were cryopreserved and shipped following first
passage and were stored in liquid nitrogen on deliver. While cells were documented at
500,000 cells per mL in 1 mL solution cell viability from ATCC is specified at >70%
following thaw. During initial plating, cells were thawed at 37°C for 1 min in warm water
bath, with cell pellet remaining partially frozen within cryovial. Prewarmed Fibroblast
Growth Media-2 (Fiboblast Basal Medium CC-3131 and FGMTM-2 BulletkitTM CC-3132,
Lonza) was used to warm cell pellet, and cells were plated as passage 2 cells in 75 cm2
treated cell culture flasks (T75, Abm® P0210) with 12-15 mL FGM-2 or on 175 cm2
treated cell culture flasks(T175, Abm® P0220) with 20-25 mL FGM-2. Cell media was
replaced in 24h, and media was subsequently replaced every 2-3 days. Subculturing
was performed when NHDF-ad reached approximately 75% confluence (deviation from
ATCC® product sheet instructions). Cells were washed with Dulbecco’s Phosphate
Buffered Saline without Calcium and Magnesium (Corning® 20-031-CV) (2 x 5 mL
washes for T75 plates, 2 x 10 mL) and treated with 0.25% Trypsin/0.53 mM EDTA
(ATCC® 30-2101) at a 1:4 ratio in PBS -Ca/-Mg (0.05% Trypsin in EDTA). Coat cells with
5 mL Trypsin solution for T75 plates, and 10 mL for T175 plate. Cells were trypsinized
for 1-2 min in 37°C cell incubator, gently tapped and examined under light microscope
for cell rounding and detachment. After successful detachment, cells were harvested
and suspended in Dulbecco’s Modified Eagle Medium (DMEM, Lonza 12-604F) with
10% Fetal bovine serum to neutralize trypsin. Cells were centrifuged at 200-210 g for 5
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min. Supernatant was discarded and cells were resuspended in media for cell count and
viability assessment. 10 ul aliquots of cells were collected, stained with 10 ul Trypan
Blue stain (0.4%), and seeded into CountessTM Cell Counting Chamber slides
(ThermoFisher Scientific C10228). Cell counts and viability fraction was attained using
CountessTM II FL Automated Cell Counter. Cells were re-plated at 3000-4000 cells/cm2
adjusted for cell viability fraction or stored cells in a cryovial with 10% DMSO. Cryovials
were cooled in -70°C freezer for 24h before storage in liquid nitrogen storage. If cell
viability is less than 70%, cells were examined for indications of continued cell death
(cell fragments in media, detached floating cells) on subsequent days. Cells were
discarded if cell viability fractions remain less than 70% in subsequent subcultures. Only
cells on their 8th-10th passage were used in experiments. After 10 subcultures, cells were
discarded.
Human adipose microvascular cells (HAMECs) were cultured under similar
conditions as NHDF-Ads; however, prior to plating, plates were pre-treated with 30
ug/mL human fibronectin (Corning® 354008 diluted in DPBS -Ca2+/-Mg2+ with 4-5 mL
coated on a T75 plate (ScienCell recommends 2 ug/cm2 coverage). Plates were
incubated for 30-45 min before fibronectin was aspirated. Fibronectin could be reused a
maximum 5 times for coating prior to disposal. HAMECs were seeded at 5000-7000
cells/cm2. Cells were incubated in Endothelial Growth Media-2 (Endothelial Basal
MediaTM CC-3156 and EGMTM BulletKitTM CC-3162, Lonza®) and subcultured at 90%
confluence. HAMECs could occasionally be driven to senescence prior to our desired 810 passage especially if plated at either too high or low a seeding density. If confluence
of cell plates did not appreciably change (>10%) in 5 days, cells were discarded.
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6.2 Rodent Cell Extraction and Culture
Sprague Dawley-Rats and C57BL/6 mice were host animals for implants and wound
models within this body of work. As such, the stromal vascular fraction of these host
animal fraction, namely the adipose-derived microvascular endothelial cells and adipose
derived adherent cells (properties resembling fibroblasts), were used to develop controls
to determine if the primary human cell implantation in the rodent hosts elicits a
xenobiotic response. The protocol detailed below, derived in part from methods
employed by Czaija et al.,[47] details how the stromal vascular fraction is extracted and
cell types are isolated from rodent epididymal fat. Extracted microvascular cells,
however, could not tolerate multiple subcultures, introducing a potential confounder in
comparisons between human-derived and rodent-derived tissue engineered constructs.
Rodents (either Sprague-Dawley or C57BL/6 mice were placed under a surgical plane of
anesthesia with 3-5% isofluorane. Rodents were oriented in a supine position, shaved
and cleaned with subsequent application of ethanol and iodine. A transverse cut was
made under the mouse ribcage. The incision was continued dorsally on both the left and
right sides of the rodents to allow skin to be retracted to reveal peritoneum and inguinal
triangles. White adipose tissue fat pads from the rodents was collected from inguinal
triangles, with careful effort made to resect around the large bowel. Epididymal and
gonadal fat pads were collected from males and females respectively.
Samples were collected in 2mL sterile filter DPBS without calcium and magnesium and
2% Penicillin/Streptomycin (GibcoTM15140122) in a pre-weighed 50mL conical tube and
placed in an ice bath. Weight of each adipose sample was recorded. A digestion buffer
was made with 2mg/mL collagenase type 1 (GibcoTM 17100017) and 6% bovine serum
albumin) in DBPS without Ca2+/Mg2+. Contents were sterile filtered using 0.22um syringe
filters. The volume of digestion buffer used per sample was calculated by multiplying 0.8
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x weight of the adipose sample in grams. Fat and digestion buffer was transferred to a
sterile 100 mL glass bottle and incubated in a 37°C water bath for a maximum of 45
minutes (or until specimen formed a slurry in the digestion buffer). The sample and
digestion buffer were shaken manually every 5 minutes for 15 seconds during the
digestion period.
DMEM with 20% Fetal bovine serume and 1% Penicillin/Streptomycin was added to
digested fat to neutralize collagenase at a 1:1 ratio. Contents were transferred to a 15
mL conical tube and centrifuged at 300g for 10 minutes at room temperature. During this
time, 2xT25 flasks were coated with 1% gelatin (1mL per flask) and 3xT25 flasks were
coated with 2% gelatin and incubated for 15 minutes at 37°C.
From the conical tube, the bulk lipid layer (floating on top) and the straw-colored
supernatant was transferred to a waste tube. The remaining cell pellet was suspended in
1mL DMEM, 10% FBS, 1% Penicillin/Streptomycin. The media was tritrated and an
additional 9 ML of media was added. The cell suspension was passed through a 70-um
cell strainer into another 15 mL conical tube, with strainer being washed with an added 2
mL of media to dislodge adherent cells. The collected cell suspension was centrifuged
again at 300g for 10 minutes at room temperature, and supernatant was discarded. The
cell pellet was resuspended in 6 mL of 1:2 EGM-2 ml to FGM-2 and then transferred to
one of the 1% gelatin-coated T25 flasks.
Serial differential adhesion steps were then taken to attempt to isolate the adherent
fibroblast-like cells from the microvascular endothelial cells. The cell-plated T25 flask
was incubated for 30 min at 37°C. The media from this flask was then collected and
transferred to the second 1% gelatin-coated T25 flask, with media replaced in the first.
The media from the second flask was then collected and plated on a third 2% gelatin
coated flask after 30 more minutes elapsed. After 1 hour, the cell media from this plate
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were then transferred to another 2% gelatin coated flask. The media from this plate was
transferred to the final plate after 2 hrs. Following extraction, media was replaced each
morning for the harvested cells. The 1st flask received FGM-2 media, the fifth flask
received EGM-2 media, and all other plates received 1:2 media. The first plate was
expected to contain primarily adherent fibroblasts, while the fifth plate was expected to
contain microvascular endothelial cells. The remaining plates were grouped according to
dominant cell types perceived through examination of cellular morphology under light
microscope. Endothelial cell purity was ascertained by conducting flow cytometry with a
primary CD31-FITC antibody tag and propidium iodide for exclusion of dead cells.

6.3 Immunohistochemistry and Immunofluorescence Staining Protocols
Both paraffin embedded and cryopreserved tissue sections obtained and stained
for hematoxylin and eosin as well as immunofluorescent markers for experiments in this
thesis.

6.3.1

Paraffinization and Sectioning

When possible, animals from which collected tissues would be paraffin-embedded were
cardiac perfused with heparinized saline, and subsequently perfused with 4%
paraformaldehyde (`7.4 pH, 310 mOsm) in PBS. For post collection fixation (if tissue
needed to be harvested from living animals), tissue was collected in 4%
paraformaldehyde in a volume ratio of at least 20:1. Paraffin embedding protocol was
adapted from Abcam (http://www.abcam.com/protocols/ihc-tissue-processing-protocol).
Samples were incubated for 2-4 hours and rinsed with PBS. Samples were then serially
dehydrated in 50,70,80,95,100% ethanol (incubated in each for 10 minutes) and
subjected to serial xylene treatments (2:1 Ethanol to Xylene, 1:1 Ethanol to Xylene, 1:2
Ethanol Xylene, and 100% xylene) for 10-15-minute incubations for each step. Finally,
samples were subjected to serial paraffin wax incubations (2:1 Xyelene to paraffin, 1:1
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Xylene to Praffin, 1:2 Xylene to Paraffin, and 100% Paraffin) for 30 minutes for each step
at 54-58°C in a vacuum oven. Sample was then placed in 100% paraffin overnight in the
oven and subsequently allowed to harden at room temperature. Ten to 15 μm sections
were attained using a LEITZ 1512 rotary microtome and appropriate microtome blades.

6.3.2

Cryopreservation and Cryosectioning

Harvested tissues were embedded in Tissue-Tek ® O.C.T. Compound (Sakura ®
Finetek) and immediately placed on dry ice to freeze. These samples were stored in 70°C freezer until cryosectioning. Cryosectioning was performed either in lab (majority of
in vitro studies) or by Margaret Romano in the Histology and Immunohistochemistry
Core at the Medical University of South Carolina (majority of in vivo studies). Five to 20
μm sections were attained using disposable, high profile microtome blade. Sections
contained at least a 2-mm margin of cryopreservative around collected specimen.

6.3.3

Immunofluorescent and Immunohistochemical Staining

Paraffin embedded sections were deparaffinized with 2x 10 min immersion in xylene at
room temperature. Sections were rehydrated with serial Ethanol immersions (100%,
95%, 70%, %0, deionized water) for 10 minutes at each step. Slides were rinsed with
deionized water, and then rehydrated in PBS in a Coplin Jar prior to blocking or,
optionally, antigen retrieval. Heat-based antigen retrieval was necessary for most
immunofluorescent stains for paraffin embedded sections and was performed using
Vector ® Antigen Unmasking Solution (citrate-based, H-3300) as per manufacturer’s
instructions.
Cryosections were rehydrated first in PBS before fixation with 2% paraformaldehyde in
PBS for 10 minutes at room temperature. Slides were then washed 3x10 min in PBS.
Sections were rarely subjected to heat-based antigen-retrieval. Sections were encircled
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with a hydrophobic barrier using a Pap pen, and then coated with blocking buffer diluted
in a 1 to 10 ratio in PBS (typically 100-250 ul for a specimen covering a third of the
space of a microscope slide). The 10x Blocking buffer was composed of 10% BSA, 0.1%
Triton-X-100, in PBS. Tissue sections with blocking buffer were placed in a humidity jar
and incubated at room temperature for 1 hour (or left in blocking buffer overnight at 4°C).
Blocking solution was then replaced with primary antibodies diluted in blocking buffer. A
comprehensive list of antibodies and dilutions used in experiments listed in this thesis is
included in). Slides were incubated overnight at 4°C. Sections were then washed with
PBS 3x10 minutes in Coplin jars. Excess liquid was removed from the slide and pap pen
was reapplied as necessary to re-enforce hydrophobic barrier. The frozen secondary
antibodies (mostly stored in -20°C) were centrifuged at 1600g and 4°C to pellet the
protein adducts formed during storage. Aliquots of secondary antibodies were collected
from supernatant to reduce non-specific background staining. Secondary antibodies
(unless using primary antibodies pre-conjugated to fluorescent tags or Horseradish
peroxidase) diluted in blocking buffer were then coated on tissue sections. Slides were
incubated in a humidity chamber for 2hrs. If desired, Hoechst nuclear counterstain
(Vendor information) was applied to slides in a 1:10000 ratio in PBS in a Coplin jar.
Hoeschst stain corresponds roughly to the DAPI excitation/emission filter settings in
fluorescent microscopy,and has its own excitation/emission settings in the Leica
confocal microscope. Sections were rinsed in PBS 2x10 minutes, and then coated with
Prolong® Gold antifade mounting media (typically 3 drops for specimen covering 1/3 the
surface of a microscope slide). A coverslip was applied with each corner tacked in place
by nail polish. Mountant was allowed to harden overnight and coverslips were
subsequently fully sealed with nail polish. When sections needed to be unmounted for
restaining, slides were soaked in warm (37°C) PBS.
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